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ABBREVIATIONS
AS anastomotic stricture
ASA American Society of Anesthesiologists grade
BMI body mass index
CCI Charlson comorbidity index
CD Crohn`s disease
CRC colorectal cancer 
CRO colorectal obstruction
CT computed tomography
DS diverticular stricture
EBD endoscopic balloon dilation
ECM extracolonic malignancies
ERC endoscopic retrograde cholangiography
ERCP endoscopic retrograde cholangiopancreatography
ES endoscopic stenting
GI gastrointestinal
GJ gastrojejunostomy
GOO gastric outlet obstruction
GOOSS gastric outlet obstruction scoring system
LGJ laparoscopic gastrojejunostomy
MRI magnetic resonance imaging
OGJ open gastrojejunostomy
PEG/PEJ percutaneous gastrostomy/ percutaneous jejunostomy
PR palliative resection
PTC percutaneous transhepatic cholangiography
PTD percutaneous transhepatic drainage
QoL quality of life 
SEMS self-expanding metal stent 
TME total mesorectal excision
WHO World Health Organization score
9ABSTRACT
Aim: Gastric outlet obstruction (GOO) is a preterminal event in incurable 
malignancies of the gastrointestinal (GI) tract. Pancreatic cancer and gastric cancer 
are the most common causes for GOO. Colorectal cancer (CRC) is the most common 
etiology for colorectal obstruction (CRO). Other causes for CRO include extracolonic 
malignancies (ECM) and benign causes. Traditional treatment of GOO and CRO 
is surgery, but it carries a high rate of complications. Self-expanding metal stents 
(SEMS) have become an alternative for surgery in GOO and CRO.
The principle aim of this work was to evaluate the results of endoscopic stenting 
in GOO and CRO. The utility of SEMS in incurable GOO was studied and the results 
of stenting, gastrojejunostomy (GJ), and palliative resection (PR) in advanced gastric 
cancer and GOO was compared. The utility of SEMS in benign CRO was studied 
and in malignant CRO, the utility of SEMS was assessed as a bridge to surgery 
and as palliation.
Patients and methods: The study material consisted of 323 patients with GOO 
or CRO treated at Meilahti Hospital between January 1998 and December 2010. 
Patients with incurable GOO (I), advanced gastric cancer and GOO (II), benign 
CRO (III), and malignant CRO (IV) treated with SEMS were identified from the 
endoscopy unit`s database. Patients who underwent GJ or PR caused by advanced 
gastric cancer were identified from the surgical unit`s database (II). For all studies, 
the data was analysed retrospectively. 
In study I, 104 patients were included in the analysis. The study II population 
consisted of 97 patients, and of these 50 underwent endoscopic stenting, 26 PR, and 
21 GJ. In study III, 21 patients were included in the analysis. The study IV population 
comprised 101 patients, and of these 11 were stented as a bridge to surgery. Of 101 
patients, 66 underwent palliative stenting due to CRC and 24 due to ECM. 
Results: In patients with incurable GOO (I), a median GOOSS (gastric outlet 
scoring system) improved significantly from 0 to 2 after stenting, and 73% of the 
patients managed with only one stenting procedure until death. Repeated stenting 
became necessary for 21 patients (20.2%). Combined enteral and biliary stenting 
succeeded in 10/11 (91%) patients. A median survival was 62 days (range 1-933). 
In patients with advanced gastric cancer (II), stenting resulted in a more rapid 
improvement in oral intake and a shorter hospital stay than GJ or PR. Complication 
rates were similar between three groups. For patients who underwent PR, symptom-
free and overall survival were longest.  In multivariate survival analysis, independent 
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prognostic factors were age, BMI, pre-procedure GOOSS, palliative resection as 
treatment modality, and chemotherapy.
In benign CRO (III), technical success of stenting was achieved for all patients 
and clinical success for 16/21 (76%) of the patients. Of eight anastomotic strictures 
(AS), five (63%) were resolved with SEMS. Of ten diverticular strictures (DS), three 
(30%) were resolved with SEMS. Complications occurred for nine patients (43%) 
in ten procedures. Of the complications, 67% occurred for patients with DS or 
Crohn`s disease strictures.
In malignant CRO (IV), overall technical and clinical success rates were 99% 
and 87%, respectively. A total complication rate was 20%. A primary anastomosis 
in elective operations was possible for 90% (9/10) of the patients who were stented 
as a bridge to surgery. In palliative stenting, clinical success rates were significantly 
lower for patients with extracolonic malignancies than for patients with colorectal 
cancer (63% vs. 94%, p<0.001). Between palliation groups, complication, operation, 
and stoma rates were similar.
Conclusions: SEMS provides good palliation for patients with incurable GOO. 
In advanced gastric cancer and GOO, SEMS is a treatment of choice for patients 
unfit for surgery. PR seems to provide survival benefit, and should be considered 
as a treatment option for patients fit for surgery. In benign CRO, SEMS is a good 
treatment option in AS for selected patients. In DS and Crohn`s disease strictures, 
a high rate of complications limit the utility of SEMS. In malignant CRO, SEMS 
can be used as a bridge to surgery and as palliation. A higher clinical failure rate is 
associated with palliative stenting for ECM than for CRC. 
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1. INTRODUCTION
Obstruction of the gastrointestinal (GI) tract occurs frequently in abdominal 
malignancies. Pancreatic cancer and gastric cancer are the most common etiologies 
of gastric outlet obstruction (GOO) (Del Piano et al. 2005). GOO limits oral intake 
and leads into malnutrition and weakening of the clinical condition of the patient. 
GOO also substantially deteriorates the quality of life (QoL) and is commonly 
associated with biliary obstruction. 
Colorectal obstruction (CRO) is most often caused by colorectal cancer (CRC). 
Of CRC patients, 15% to 20% experience an obstruction of the bowel (Kyllonen 
1987). CRO can be also caused by extracolonic malignancies (ECM) such as ovarian 
cancer or by benign etiology.
The traditional treatment for GOO is gastrojejunostomy (GJ). After GJ, a relief 
of symptoms is achieved in about 80% of the patients (Jeurnink et al. 2010). GJ is 
associated with a high rate of complications, however. An important complication is 
delayed gastric emptying, occurring in 11% to 57% of the patients, which can prevent 
oral intake, despite the technical success of a procedure (Doberneck and Berndt 
1987; Woods and Mitchell 1989). In advanced gastric cancer, surgical treatment 
options for GOO include GJ and palliative resection (PR) (Ouchi et al. 1998).
The standard approach in malignant CRO is surgery. Emergency surgery for 
acute CRO is associated with higher morbidity and mortality rates than elective 
surgery (Runkel et al. 1991). In addition, patients undergoing emergency surgery 
have poorer 5-year survival than patients who are operated on electively (McArdle 
and Hole 2004). For incurable metastasized disease, palliative surgery options 
for obstruction include bowel resection, colostomy, or entero-enterostomy. A 
multidisciplinary team is recommended when planning the treatment for each 
patient. The standard management of benign CRO caused by anastomotic strictures 
(AS), diverticular strictures (DS), or Crohn`s disease (CD) strictures is endoscopic 
dilation or surgery. Multiple endoscopic procedures are often needed when treating 
AS or CD strictures (Stienecker et al. 2009; Suchan et al. 2003).
Self-expanding metal stents (SEMS) were introduced as a treatment alternative 
for obstructions of the GI tract in the 1990s (Dohmoto 1991; Kozarek et al. 1992). As 
a palliative method for GOO, SEMS have shown to result in a more rapid tolerance 
of oral intake, less morbidity, lower incidence of delayed gastric emptying, and 
shorter hospital stay than GJ (Hosono et al. 2007). Rather little data exists on 
combined biliary and enteral stenting, but the results have been promising (Kaw et 
al. 2003). SEMS have also been used in malignant and benign CRO. In preoperative 
stenting of acute malignant CRO, SEMS have resulted in higher primary anastomosis 
rates and lower stoma rates than emergency operations (Cennamo et al. 2013). In 
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palliation of CRO, SEMS have been associated with shorter hospital stay and fewer 
complications than palliative surgery (Ptok et al. 2006). Data on SEMS and CRO 
caused by ECM is limited, and the results vary (Keswani et al. 2009). SEMS have 
also been used in benign CRO, but there is only little data on this subject (Small 
et al. 2008).
In this thesis, efficacy, safety, and outcome of endoscopic stenting in GI tract 
obstructions were evaluated. The efficacy of SEMS in malignant incurable GOO was 
studied, and compared to the results of stenting to GJ and PR in advanced gastric 
cancer. The feasibility of combined stenting in biliary obstruction and duodenal 
obstruction was also studied. The utility of SEMS in benign CRO was evaluated. 
In malignant CRO, the feasibility of SEMS as a bridge to surgery and as palliation 
was assessed. The outcomes of palliative stenting between two etiologies, primary 
CRC and ECM, was also compared.
13
2. REVIEW OF THE LITERATURE
2.1 MALIGNANT GASTRIC OUTLET OBSTRUCTION
2.1.1 DEfINITIONS AND CLINICAL pRESENTATION
Gastric outlet obstruction (GOO) or gastroduodenal obstruction is a condition where 
the normal outflow from the stomach is obstructed. Obstruction can develop from 
the intraluminal tumour growth, tumour ingrowth from surrounding structures, or 
from extraluminal tumour compression. GOO causes nausea, vomiting, and early 
satiety which result in dehydration and malnutrition, and eventually weakening 
of the clinical condition of the patient. The symptoms of GOO substantially limit 
the quality and quantity of the remaining life of the patient. The gastric outlet 
obstruction scoring system (GOOSS) (Table 1) was presented by Adler (Adler and 
Baron 2002), and can be used to define a patient`s ability of oral intake. 
Table 1. The Gastric Outlet Obstruction Scoring System (GOOSS)
Level of oral intake Score
no oral intake 0
Liquids only 1
soft solids 2
Low-residue or full diet 3
2.1.2 ETIOLOGy AND DIAGNOSIS
Malignant GOO is caused by advanced malignancies of the upper-GI tract. 
Pancreatic and gastric carcinomas are the most common causes of GOO; additional 
causes include other periampullary tumours than pancreatic head (duodenum, 
distal bile duct, ampulla of Vater), lymphoma and metastases of other malignancies 
(Del Piano et al. 2005; Jeurnink et al. 2010). 
2.1.2.1. Pancreatic cancer 
In developed countries, pancreatic cancer is the ninth most common cancer 
diagnosis with an estimated 165,000 new cases diagnosed annually, and the fifth 
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most common cause of cancer death for men and the fourth for women. In developing 
countries, pancreatic cancer is rarer (Jemal et al. 2011). Approximately 1000 new 
pancreatic cancers are diagnosed annually in Finland.  Although representing 
only 3.5% of all new cancer diagnoses, up to 9% of cancer deaths are caused by 
pancreatic cancer in Finland. The prognosis of pancreatic cancer is extremely 
poor; a five-year survival is only 5% (Finnish cancer registry). Surgical resection 
by pancreaticoduodenectomy is the treatment of choice for pancreatic cancer. Of the 
patients with periampullary tumours who undergo exploratory laparotomy with an 
intention to perform pancreaticoduodenectomy, 25% to 75% are found to have an 
unresectable disease (Singh et al. 1990; Trede 1985). Symptomatic GOO develops 
in 19% to 41% of patients with pancreatic and periampullary cancers and therefore 
prophylactic gastrojejunostomy is indicated with unresectable patients undergoing 
exploratory laparotomy (Lillemoe et al. 1999; Van Heek et al. 2003). 
2.1.2.2. Gastric cancer
In developed countries, gastric cancer is the fifth most common cancer diagnosis with 
an estimated 275,000 new cases diagnosed annually, the fourth most common cause 
of cancer death for men and the fifth for women. In developing countries, gastric 
cancer is more common. Over 70% of new cases and deaths occur in developing 
countries (Jemal et al. 2011). In Finland, approximately 700 new diagnoses are 
made annually. In spite of declining incidence of gastric cancer, it is the fifth most 
common cause of cancer death for men and the sixth for women with five-year 
survival of 25% (Finnish cancer registry). Surgical resection is the treatment of 
choice for gastric cancer. Unfortunately, a significant number of patients have an 
advanced disease at the time of the diagnosis, and curative surgery is possible for 
only 20% to 50% of the patients (Akoh et al. 1991; Allum et al. 1989; Kokkola et al. 
2008). Cardia of the stomach is the most common location of tumour, in 37% of 
patients, followed by antrum in 20%, corpus in 5%, fundus in 4%, pylorus in 3%, 
and multiple or overlapping locations in 31% (Cunningham et al. 2005). In antral 
gastric cancer, the incidence of GOO is 15% (Watanabe et al. 1998).
The diagnosis of malignant GOO is based on clinical symptoms, malignant 
histology, endoscopy findings of tumour obstruction, and radiologic examinations 
such as computed tomography (CT), magnetic resonance imaging (MRI), 
ultrasound,and oral contrast meal study (Figure 1)
15
2.1.3 pALLIATION Of GASTRIC OUTLET OBSTRUCTION
The World Health Organization (WHO) has defined palliative care as “the total 
active care of patients whose disease is not responsive to curative treatment. Control 
of pain, of other symptoms, and of psychologic, social, and spiritual problems is 
paramount. The goal of palliative care is the achievement of the best quality of life 
for patients and their families.” (WHO 1990). Palliation should not be regarded 
as an opposite of cure. For patients suffering from symptoms of GOO, the goal of 
palliative treatment is to maintain oral food intake and to prevent worsening of 
clinical condition due to vomiting, dehydration, and malnutrition. As the median 
survival of patients with unresectable pancreatic cancer is 3-6 months (Ghaneh et 
al. 2007) and with advanced gastric cancer 9-13 months (Miner et al. 2004) it is 
essential that the palliation of symptoms of GOO is fast, with low morbidity, and 
with short hospital stay.
2.1.3.1. Open and laparoscopic gastrojejunostomy
The standard treatment for GOO has been open gastrojejunostomy (OGJ). In this 
procedure, through midline or rooftop incision, a jejunal loop 40-60 cm distal 
to the ligament of Treitz is used to form an antecolic or retrocolic side-to-side 
gastrojejunostomy. An anastomosis can be either hand-sewn or stapled to the 
anterior or posterior surface of the stomach.
figure 1. Abdominal plain x-ray and CT images of stricture located in pylorus causing dilation and 
retention of stomach
16
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Previous prospective studies have demonstrated the technical success rate of OGJ 
to be 94% to 100% (Fiori et al. 2004b; Jeurnink et al. 2010; Johnsson et al. 2004). 
After OGJ, relief of obstructive symptoms is achieved in 66% to 83% of the patients. 
A high rate of complications limits the usefulness of OGJ in the treatment of GOO. 
Earlier studies have reported a high complication rate even up to 90% with patients 
undergoing OGJ (Doberneck and Berndt 1987; Weaver et al. 1987). Complications 
may be major or minor. Major, life threating, complications associated with OGJ 
include anastomotic leakage, perforation and peritonitis, and postoperative 
haemorrhage. Minor complications include delayed gastric emptying, wound 
infections, and pain (Jeurnink et al. 2010). More previous studies report major 
complication rates up to 13%, and minor up to 30% (Fiori et al. 2004b; Jeurnink 
et al. 2010; Johnsson et al. 2004). One of the complications after OGJ is delayed 
gastric emptying, which can lead to clinical failure. Etiology for this complication 
can be a diminished motility of the dilated stomach and unphysiologic passage 
of food. In earlier studies, the occurrence of delayed gastric emptying has been 
between 11% and 57% (Doberneck and Berndt 1987; Woods and Mitchell 1989). 
More recent prospective studies report a slightly diminished rate of delayed gastric 
emptying between 11% and 30% (Fiori et al. 2004b; Jeurnink et al. 2010). After 
OGJ, median hospital stay has been between 10 days and 15 days. 
As mini-invasive techniques have evolved, laparoscopic gastrojejunostomy (LGJ) 
has become a treatment alternative for GOO. Compared to OGJ, LGJ has been 
proposed to result in more rapid improvement in oral intake and symptom relief, 
reduction of post-operative morbidity, and shorter hospital stay. Limited data on the 
usefulness of LGJ in the treatment of malignant GOO exists, however. Croce et al. 
(Croce et al. 1999) performed 25 LGJs with a complication rate of 4% (1/25) and a 
median post-operative hospital stay of 3 days.  In a retrospective report, comprising 
16 patients with malignant and 12 patients with benign GOO, the reported major 
and minor complication rate was 14% and 18%, respectively, with a median hospital 
stay of 8 days (Zhang et al. 2011). In a prospective study by Mehta et al. (Mehta et 
al. 2006), the complication rate was 61% and mean hospital stay 11 days. 
In two retrospective comparative studies, compared to OGJ, LGJ resulted in 
a shorter hospital stay (Al-Rashedy et al. 2005;  Bergamaschi et al. 1998), less 
estimated intraoperative blood loss (Bergamaschi et al. 1998), shorter duration 
of postoperative intravenous hydration and opioid analgesia, and morbidity (Al-
Rashedy et al. 2005). The clinical outcomes of OGJ and LGJ in GOO were compared 
in a prospective randomized trial. Results from the study show less intraoperative 
blood loss (38 ml vs. 170 ml), fewer postoperative complications (0% vs. 16%), and 
faster tolerance of oral intake (4 days vs. 6 days) in the LGJ group compared to 
OGJ (Navarra et al. 2006). 
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2.1.3.2. Palliative resection in gastric cancer
A significant number of gastric cancer patients present with locally advanced or 
metastasized disease excluding curative surgery. Non-curative resection in gastric 
cancer is by definition patients without major symptoms undergoing resection 
with microscopic (R1) or macroscopic (R2) tumour residual, or with metastatic 
disease (M1) disease (Miner et al. 2004). In many cases, non-curative operations are 
started (R2) or performed (R1) with a curative intent. Palliative surgery of advanced 
malignancy can be defined as a procedure intended to improve patients` QoL or 
to relieve symptoms (McCahill et al. 2002; Miner et al. 1999; Miner et al. 2002). 
For locally advanced and/or metastasized gastric cancer, palliative chemotherapy 
is the treatment of choice. Compared to supportive care only, palliative chemotherapy 
provides survival benefit and improvement in QoL (Glimelius et al. 1997; Murad 
et al. 1993; Pyrhonen et al. 1995). A role of non-curative surgery in the absence 
of major symptoms for gastric cancer is unclear due to lack of sufficient data. No 
randomized studies comparing non-curative resection with chemotherapy versus 
chemotherapy alone exist, and the study populations are heterogeneous consisting of 
patients with and without major symptoms. Some studies have reported improved 
survival after non-curative surgery, particularly if metastatic sites are limited to two 
at most (Hartgrink et al. 2002; Haugstvedt et al. 1989; Samarasam et al. 2006). 
Resection combined with chemotherapy has also been beneficial in terms of survival 
(Chang et al. 2012; Lin et al. 2008; Saidi et al. 2006). Some studies have found 
no survival benefit after resection (Kokkola et al. 2012; Ouchi et al. 1998; Park et 
al. 2009a). Morbidity rates after resection have ranged between 13% to 38% and 
mortality rates between 0% and 12% (Chang et al. 2012; Hartgrink et al. 2002).
 In the event of major symptoms, such as bleeding or GOO, palliation of symptoms 
becomes essential. The options for palliation include palliative surgery with resection 
or bypass, or stent deployment. Based on the possible survival benefit after resection, 
PRs in the event of GOO are widely performed. The suitability of the patient for major 
operation, such as resection should be carefully discussed. The nutritional status 
and general health for patients with GOO are often poor. Nutritional deficiency has 
been regarded as a significant factor for postoperative complications in abdominal 
surgery (Sungurtekin et al. 2004). Preoperative symptoms of GOO for patients 
undergoing curative resections for gastric cancer adversely affect overall survival 
(Park et al. 2009b). Also in advanced disease, it has been shown that survival is better 
for asymptomatic patients undergoing non-curative resections than for patients 
with major symptoms undergoing PRs (Miner et al. 2004). Similarly, a study by 
Kahlke et al. (Kahlke et al. 2004), consisting of gastric cancer patients undergoing 
PR or exploration only, showed that the intensity of preoperative symptoms affects 
survival and is shortest for patients with major symptoms like GOO. Survival was 
not influenced by the type of operation. QoL is an important issue in palliation, 
particularly when considering operative treatment, but little data exists on the 
18
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subject. Kahlke et al. (Kahlke et al. 2004) used a standardized EORTC QLQ-C30 
questionnaire to measure QoL before and after operation. QoL did not differ in 
patients with major and minor symptoms preoperatively. For patients with major 
symptoms, general QoL was significantly better before discharge and at 3 months 
after operation than for patients with minor symptoms.
2.1.3.3. Self-expanding metal stents in gastric outlet obstruction
2.1.3.3.1.	Definition,	stenting	technique,	and	stent	types
A self-expanding metal stent (SEMS) is a cylindrical prosthesis made of cross-
hatched, braided or interconnecting rows of metal that are assembled into a tube-
like structure (Figure 2). SEMS are typically used as a palliative treatment for 
obstructions in the GI tract.
SEMS was introduced as palliation of GOO in the early 1990s. In 1992, 
Topazian (Topazian et al. 1992) used SEMS for palliation of obstructing gastric 
cancer and Kozarek (Kozarek et al. 1992) for stenosis of afferent and efferent loop. 
Since then, SEMS have been increasingly used for palliation of malignant GOO. A 
SEMS can be deployed under endoscopic, fluoroscopic, or combined endoscopic 
and fluoroscopic control. Fluoroscopic technique is preferred by interventional 
radiologists. Before the stenting procedure, the stomach should be decompressed 
with a nasogastric tube. In the combined technique, the insertion of a guidewire 
or stent through the disfigured stomach is usually easier. Procedures are usually 
figure 2. Uncovered stents: colonic SEMS (above), duodenal SEMS (middle), and biliary SEMS 
(bottom)
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performed under conscious sedation. In combined endoscopic and fluoroscopic 
technique, the stricture is approached with a therapeutic gastroscope or side viewing 
duodenoscope. A guidewire and a catheter are passed beyond the stricture. A 
contrast media is injected to confirm successful passage through the stricture, to 
assess the morphology and length of the stricture, and to assure correct position 
of the guidewire. For larger diameter stents, the endoscope is removed and the 
stent delivery system is deployed over the wire. Smaller diameter stents can be 
deployed through the working channel of the endoscope. A stent length should be 
2 to 4 cm longer than the stricture in case of possible shortening of the stent and 
for preventing migration. (Mauro et al. 2000).  
An ideal stent should be easy to deploy, with a wide enough internal diameter to 
restore normal eating, and with sufficient radial force to expand inside hard tumour 
tissue. Stents should be strong enough to prevent stent fractures and collapses; 
at the same time they should be flexible to conform to angled strictures. Stents 
should also hold their length, stay in the position, and prevent tumour ingrowth and 
subsequent stent obstruction. Two main types of SEMS are available –uncovered 
and covered– with their own advantages and disadvantages (Figure 3). The majority 
of the stents used are uncovered. Uncovered stents get more easily obstructed in the 
long-term due to tumour ingrowth through small openings between the stent wire 
filaments (Graber et al. 2007; Nevitt et al. 1998).  Covered stents have a membrane 
that prevents the tumour ingrowth, but migration occurs more frequently (Jeong 
et al. 2002; Jung et al. 2000). In two recent prospective studies, of which one 
was randomized, comparing uncovered and covered stents as palliation of GOO, 
figure 3. Covered SEMS
20
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the technical and clinical success rates were comparable (Kim et al. 2010;  Lee 
et al. 2009). In both studies, migration rate was higher for covered stents than 
for uncovered stents (17%-25% vs. 0%-3%). Recurrent obstruction due to tumour 
ingrowth was more common for uncovered stents (16%-25% vs. 0%-3%). There was 
no difference in stent patency time and overall survival. To resolve the problems of 
migration and reobstruction, newly designed double-layered or partially covered 
stents have been introduced. The reported migration rates have ranged between 
6% and 10%, and reobstruction rates between 10% and 18% (Isayama et al. 2012; 
Kim et al. 2011).
2.1.3.3.2. Overall outcome
A 2004 meta-analysis pooled data from a total of 32 case series between 1992 
and 2003 (10 prospectively collected) with 606 patients (Dormann et al. 2004). 
Technical success of SEMS placement was achieved in 97%, and clinical success 
in 89% of those in whom technical success was achieved. Total complication rate 
was 28%. Of complications, perforation or bleeding occurred in 1%, stent migration 
in 5%, and recurrent obstruction in 18% of the patients. There was no procedure 
related mortality. 
In more previous prospective single centre reports, the technical success rate 
of SEMS deployment as palliation for GOO has ranged between 91% and 94% and 
clinical success rate between 88% and 94%. Total complication rate has ranged 
from 11% to 24% (Havemann et al. 2009; Holt et al. 2004; Kim et al. 2007). In 
multicentre studies, the technical success rates have been between 95% and 98%, 
and clinical success rates between 77% and 92%. Total complication rates have 
ranged from 15% to 36% (Costamagna et al. 2012;  Graber et al. 2007;  Nassif et 
al. 2003;  Piesman et al. 2009;  Telford et al. 2004;  van Hooft et al. 2009). The 
majority of the stents used in the aforementioned studies are uncovered stents. Major 
complications associated with SEMS placement include perforation of the bowel 
and bleeding. Reported rate for perforation has ranged between 1% and 5% and for 
bleeding between 1% and 6%. The most common late complication, occurring with 
a rate of 9% to 22%, is stent obstruction which can develop due to tumour ingrowth 
or due to tissue granulation, or from extrinsic compression of the surrounding 
tumour resulting in stent collapse. Treatment options for stent obstruction include 
repeated stenting, endoluminal endoscopic procedures such as laser ablation, or 
surgery. Stent migration rate has been up to 7%. Other complications related to stent 
placement include cholangitis and abdominal pain. Most of the studies report no 
procedure related mortality. However, Graber et al. (Graber et al. 2007) reported 
stent placement related mortality in 5 of 51 (9.8%) patients with major complications. 
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2.1.3.4. Self-expanding metal stents versus gastrojejunostomy in gastric outlet 
obstruction
2.1.3.4.1.	Efficacy	and	safety
According to a meta-analysis, consisting of one randomized prospective trial and 
eight retrospective studies (307 patients) published between 2001 and 2006, 
endoscopic stenting was associated with higher clinical success (p=0.007), a shorter 
time for tolerance of oral diet (p<0.001), less morbidity (p=0.02), lower incidence 
of delayed gastric emptying (p=0.002), and a shorter hospital stay (p<0.001) than 
surgical gastrojejunostomy. Between the groups, no significant difference was found 
in 30-day mortality (Hosono et al. 2007). 
 Since this meta-analysis, two randomized studies have compared the results 
of SEMS placement and gastrojejunostomy. Mehta et al. (Mehta et al. 2006) 
randomized 27 patients to the LGJ (n=14) or stent group (n=13). Eight patients in 
the LGJ group had a complication which included delayed gastric emptying (n=3), 
hematemesis (n=2), port site infection (n=1), deep venous thrombosis (n=1), and 
respiratory tract infection (n=1). All complications were managed conservatively. No 
complications occurred in the stent group. Hospital stay was shorter in the SEMS 
group (5.2 days vs. 11.4. days). The authors reported no times for restoration of 
oral intake. The cumulative survival rates were similar among groups. In another 
study, 18 patients were randomized to the GJ group and 21 to the stent group. 
For the stent group, the tolerance of oral diet was faster (GOOSS ≥ 2: median 
5 vs. 8 days) and hospital stay shorter (median 7 vs. 15 days) than for the GJ 
group. The long-term relief was better for GJ (GOOSS ≥2: 72 vs. 50 days). In 
the stent group, more major complications, recurrent obstructive symptoms, and 
reinterventions were recorded. There was no difference in survival (Jeurnink et al. 
2010). In a prospective, non-randomized study, comparing SEMS, GJ and PEG/
PEJ (percutaneous gastrostomy or percutaneous jejunostomy), 50 patients were 
enrolled to a cohort (Schmidt et al. 2009). After withdrawal of three patients, 47 
were included into analysis. Stenting was attempted in 34 patients with a success 
rate of 25/34 (74%). Ten patients were initially operated on. Six patients from the 
stent group underwent GJ, thus, eventually there were 16 patients in the GJ group. 
Three patients underwent PEG/PEJ initially, as well as four patients who failed 
stent placement, leaving seven patients to the PEG/PEJ group.  A median hospital 
stay was shortest for the SEMS group (SEMS 2.5 vs. GJ 10 vs. PEG/PEJ 9 days). 
There were no significant differences in tolerance of oral diet at 1 or 3 months, 30-d 
mortality, or need for reinterventions  due to recurrent GOO. A median survival 
did not differ between SEMS and GJ groups (94 vs. 73 days).
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2.1.3.4.2.	Long-term	outcome	and	predictive	factors	for	stent	patency	
and	complications
For patients with incurable malignancies and symptoms of GOO, the patency of 
the stent is an important issue. After SEMS placement, 48% to 63% of the patients 
tolerate solid food until death (Canena et al. 2012; Piesman et al. 2009). According 
to a report of 51 patients after 135 days of SEMS placement, for 75% of the patients 
a stent remained patent (van Hooft et al. 2009). 
As shown by several studies, chemotherapy is a prognostic factor for longer stent 
patency (Kim et al. 2012; Kim et al. 2007; Telford et al. 2004). The mechanism 
for longer patency is probably due to decrease in tumour mass which results in 
diminished chance of stent collapse and tumour ingrowth into the stent. At the same 
time, increased rate of migration is associated with administration of chemotherapy 
after SEMS placement. The etiology of the malignancy may also effect outcome 
and complications. Stent collapse is more frequent in gastric cancer, but major 
complications, such as perforation and bleeding are more commonly related to 
pancreatic cancer (Kim et al. 2009a).
Clearly, the patency of the stent depends on the patient`s clinical condition and 
prognosis of the malignancy. Ascites and poor performance status are predictive 
factors for poor solid food intake (Sasaki et al. 2012). For patients with symptoms of 
GOO, poor WHO performance status, pain and use of opioid analgesia are prognostic 
factors for short survival (Jeurnink et al. 2011; van Hooft et al. 2010).  As some 
studies have reported a higher rate of late complications for stent placement than 
for GJ, it has been suggested that GJ should be preferable treatment for patients 
with good performance status and life expectancy over 2 months (Jeurnink et al. 
2010; No et al. 2013). 
2.1.3.4.3.	Quality	of	life	and	costs
The evaluation of quality of life (QoL) when treating malignant GOO is difficult 
due to lack of sufficient data. For OGJ, most QoL scores are shown to deteriorate 
temporarily after surgery, but they are restored to initial levels within 4 months 
(Van Heek et al. 2003). A problem with gathering data from the QoL aspect is 
that different questionnaires are used, and often only physical function is assessed 
which is considered inadequate for evaluation of GOO (Fayers and Machin 2007). 
In two prospective, randomized studies, QoL was assessed (Jeurnink et al. 
2010; Mehta et al. 2006). An improved physical health at one month after stent 
placement, measured by using the Short-Form-36 (SF-36) questionnaire, was found 
by Mehta et al. (Mehta et al. 2006). A significant increase in pain was found at day 
one after LGJ; no difference was found in the SEMS group (Mehta et al. 2006). The 
pain scores (EuroQol-VAS) decreased faster after SEMS placement than after GJ. 
Other QoL scores were similar between stent and GJ groups (Jeurnink et al. 2010). 
In a prospective study by Schmidt et al. (Schmidt et al. 2009), at three months, SEMS 
placement was associated with significant improvement in global health status and 
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nausea and vomiting assessed by the EORTC QLQ-C30 instrument. Gastric-specific 
symptoms such as dysphagia, eating restrictions, dry mouth and reflux, assessed 
by the EORTC QLQ-STO22 instrument, improved in stented patients. GJ was 
associated with improvements in dysphagia and eating restrictions, but decrease 
in physical functioning at one month after operation (Schmidt et al. 2009). Other 
prospective studies found no difference in QoL before and after SEMS placement 
(Dolz et al. 2011; Piesman et al. 2009; van Hooft et al. 2009).
In a prospective, randomized study by Jeurnink et al. (Jeurnink et al. 2010), 
total medical costs were higher for the GJ than for the stent group ($16535 vs. 
$11720). Similarly in other studies, stent placement was cost-effective compared to 
GJ (Mittal et al. 2004; Roy et al. 2012; Yim et al. 2001). Johnsson et al. (Johnsson 
et al. 2004), however, reported no significant difference in total medical (comprising 
initial and all additional procedures until patient’s death) costs.
2.1.4 GASTRIC OUTLET OBSTRUCTION AND BILIARy OBSTRUCTION
Up to 75% of the patients with pancreatic cancer have symptomatic biliary obstruction 
due to tumour infiltration into the intrapancreatic portion of the common bile duct 
(Sohn et al. 1999). Patients with malignant GOO often have symptomatic biliary 
obstruction.  The treatment options for biliary obstruction include surgical bypass 
(usually hepaticojejunostomy), endoscopic retrograde cholangiopancreatography 
(ERCP) with stent placement, and percutaneous transhepatic cholangiography/
drainage (PTC/PTD). Compared to surgical bypass, the endoscopic approach is 
considered an initial treatment for biliary obstruction due to lower complication 
rate and shorter hospital stay (Shepherd et al. 1988; Smith et al. 1994). Endoscopic 
stenting has proved to be more cost-effective and provide better QoL than surgery 
(Artifon et al. 2006; Raikar et al. 1996). Endoscopic stenting has shown higher 
success and lower complication rates than PTC, and is thus also the first line 
treatment over PTC (Speer et al. 1987). Biliary stent options include plastic and 
SEMS. Plastic stents can be removed and are recommended if the resectability 
of the tumour is unclear. Patency for plastic stents is 3 to 4 months, occlusion 
resulting in a need of stent exchange (Davids et al. 1992; Prat et al. 1998). SEMS 
remain patent longer, but are more expensive than plastic ones. According to a cost 
analysis, metallic stents are advantageous in patients surviving over 6 months (Prat 
et al. 1998). Also for extremely elderly patients, plastic stent is effective enough in 
the treatment of biliary obstruction (Gronroos et al. 2010).
Biliary obstruction usually develops before duodenal obstruction, when it most 
often can be treated with a biliary stent, but it can also occur simultaneously or 
after the duodenal obstruction (Kaw et al. 2003; Mutignani et al. 2007). Very little 
data exists regarding combined biliary and duodenal stenting, and the case series 
are rather small. In the event of simultaneous obstruction of common bile duct and 
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duodenum, usually the biliary obstruction is treated first due to difficulty to access the 
papilla Vateri through enteral SEMS. Simultaneous, endoscopic stenting has shown 
success rates of 86% to 94% (Kaw et al. 2003; Maire et al. 2006; Mutignani et al. 
2007). The endoscopic biliary stenting success rates for recurrent biliary obstruction 
after combined stenting range between 50% and 100%. The number of patients 
treated is small, however (Kaw et al. 2003; Maire et al. 2006; Mutignani et al. 2007). 
Another option for combined endoscopic stenting is to treat biliary obstruction by 
means of PTC. The results show similar success rates compared to a combined 
endoscopic approach (Akinci et al. 2007; Profili et al. 2003).
2.2 COLORECTAL OBSTRUCTION
2.2.1 ETIOLOGy AND DIAGNOSIS
The clinical picture of colorectal obstruction (CRO) can range from an incidental 
tight stricture found in colonoscopy, surgery, or radiologic examinations, to an acute 
and complete obstruction. Up to 80% of the cases of CRO are caused by malignancy 
(Valerio and Jones 1978).
The symptoms of CRO include abdominal pain, distension, constipation, and 
vomiting. Abdominal distension is more likely in the event of a closed bowel 
loop or competent ileocecal valve. In contrast, vomiting is more common when 
the ileocecal valve is incompetent, allowing colonic decompression into the small 
bowel. The diagnosis of obstruction is based on symptoms, clinical examination, 
and endoscopic and/or radiologic examinations. The diagnosis of non-acute CRO 
is usually confirmed by colonoscopy which also enables the histological diagnosis. 
Radiologic examinations include plain x-ray of the abdomen, oral contrast meal 
study, CT, and MRI.
2.2.1.1. Malignant etiology for obstruction
Colorectal cancer (CRC) is the third most common cancer for men worldwide and 
the second for women with an estimated 1.2 million new cases diagnosed annually. 
CRC is the fourth most common cause of cancer deaths for men and the third for 
women with an estimated 600,000 deaths per year. In developed countries, the 
incidence rates are highest (Jemal et al. 2011). In Finland, approximately 2700 new 
CRCs are diagnosed annually, and of them 1000 (37%) are rectal cancers (Finnish 
cancer registry). CRC is the most common cause of acute CRO which occurs in 
15% to 20% (Kyllonen 1987; Phillips et al. 1985; Umpleby and Williamson 1984) 
of the CRC patients.  Among patients with CRO, older patients are the majority 
(Anderson et al. 1992). The left side of the colon is the most common place for 
acute obstruction (Tekkis et al. 2004).
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CRO can also be caused by extracolonic malignancies (ECM). Intracolonic metastases 
of other carcinomas, melanoma, or lymphoma can cause intrinsic bowel obstruction. 
Pelvic malignancies, such as ovarian, endometrium, bladder, and prostate cancers 
can lead into extrinsic compression and obstruction of the bowel. Furthermore, 
peritoneal carsinomatosis of, for example, breast, gastric or pancreatic cancer can 
cause bowel obstruction. Bowel obstructions may be multifocal involving both small 
and large bowel. Multifocal obstruction was detected in 76% of patients in an autopsy 
series of ovarian cancer (Dvoretsky et al. 1988). For ovarian cancer, the reported 
rate of large bowel obstruction is up to 33% (Rubin et al. 1989). 
2.2.1.2. Benign etiology for obstruction
A minority of colorectal obstructions are caused by benign etiology. The rate of 
anastomotic strictures after colorectal surgery is 3% to 30% (Luchtefeld et al. 1989). 
Diverticular stricture occurs in 7% of all cases of diverticular disease (McConnell et 
al. 2003). In Crohn`s disease, up to 33% of patients will develop strictures within 
10 years of diagnosis (Cosnes et al. 2002). Also in advanced cancer, the obstruction 
can be caused by benign causes such as adhesions, post radiation strictures, or 
hernia (Spears et al. 1988; Tunca et al. 1981). 
2.2.2 SURGICAL MANAGEMENT Of MALIGNANT COLORECTAL 
OBSTRUCTION
Acute CRO is a surgical emergency. Obstruction leads to perforation of the bowel, 
sepsis, and death if left untreated. Emergency surgery for acute CRO has been 
associated with a morbidity rate of 40% to 50% and a mortality rate of 15% to 
20% ( Phillips et al. 1985; Smothers et al. 2003; Tekkis et al. 2004), which are 
higher than in elective operations (Runkel et al. 1991; Runkel et al. 1998; Smothers 
et al. 2003). Other risk factors than emergency operation for increased mortality 
include patients age greater than 65 years, ASA greater than 1, Dukes staging other 
than A (Tekkis et al. 2004), and preoperative renal failure (Tan and Sim 2010). 
In addition, it is shown that CRC patients presenting as surgical emergencies are 
older and have more advanced cancer (Scott et al. 1995). Moreover, 5-year survival 
for patients undergoing emergency colorectal operations has shown to be poorer 
than for electively operated patients (McArdle and Hole 2004; Paulson et al. 2010).
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2.2.2.1. Non-palliative surgery
In general, surgical options for colorectal obstruction depend on the location of 
the tumour, extent of the disease, the patient`s clinical status and co-morbidities, 
and surgeon`s experience. In all colorectal resections, the principles of oncologic 
resection should be followed. The feeding artery of the tumour should be ligated at 
its origin for allowing adequate lymphadenectomy. The tumour and its mesocolon 
should be resected en bloc with distal and proximal margins of 5 cm to 10 cm 
(Nelson et al. 2001). For rectum tumours, the treatment of choice is total mesorectal 
excision (TME) (Heald et al. 1982) where the rectum and mesorectum with its 
lymphovascular structures within the fascia propria are excised enbloc. 
Widely accepted procedure for obstructions located between the cecum and 
the splenic flexure is right hemicolectomy, extended if necessary, with primary 
anastomosis (Fielding et al. 1979; Finan et al. 2007; Phillips et al. 1985). The 
management of acute left-sided CRO is controversial and various surgical strategies 
exist. The classic three-stage operation in which primarily diverting colostomy is 
performed to decompress bowel, followed by definitive bowel resection, and finally 
the stoma closure has been challenged because of prolonged hospital stay and 
the need for multiple procedures. Primary resection with end-colostomy, known 
as Hartmann`s procedure is a safe option in the event of acute CRO (Meyer et 
al. 2004). It is widely performed since the patients presenting with large bowel 
obstruction are often critically ill having increased risk for morbidity and mortality. 
Hartmann`s procedure enables tumour resection without a risk for anastomotic 
leakage, and it can be performed by a less experienced surgeon. Disadvantages for 
Hartmann`s procedure include a stoma formation, and a need for a major operation 
for stoma reversal. The reversal rate of Hartmann`s procedure for diverticulitis 
is approximately 50% (Salem et al. 2005). However, for patients undergoing 
Hartmann`s operation due to CRC, the reversal rate is much lower, even less than 
10% (David et al. 2009). It is shown that colostomy significantly diminishes patient`s 
quality of life (Marquis et al. 2003; Nugent et al. 1999). Moreover, Hartmann`s 
reversal carries a morbidity rate of 29% to 54% of which anastomotic leakage 
comprises 2.3% to 16% (David et al. 2009; Pearce et al. 1992; Roque-Castellano et 
al. 2007; Wigmore et al. 1995). Reported mortality associated with reversal is up 
to 3.75% (David et al. 2009; Pearce et al. 1992). 
For left-sided large bowel obstruction, one-stage primary resection with 
anastomosis is now widely preferred due to the advantage that it is a definitive 
procedure without need for further surgery (Finan et al. 2007). Mortality rates 
for one-stage operation have shown to be comparable or lower than for staged 
operations (0%-22% vs. 9%-33%) (Fielding and Wells 1974; Kasperk et al. 1992; Lau 
et al. 1995; Watters 1969). The options for one-stage operation include subtotal 
colectomy or segmental resection. In the case of a dilated proximal colon with 
ischemia, serosal tear, or perforation, subtotal colectomy is indicated. The benefits 
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for subtotal colectomy include that it deals with a risk (approximately 7%) of 
synchronous tumours of the proximal colon and usually there is no need for stoma 
creation due to a rich blood supply in the terminal ileum (Arnaud and Bergamaschi 
1994; Halevy et al. 1989).  The disadvantages for subtotal colectomy include the 
procedure’s `extensiveness and high incidence of postoperative diarrhea (Arnaud 
and Bergamaschi 1994; Halevy et al. 1989; Hennekinne-Mucci et al. 2006).  A 
prospective randomized study (The SCOTIA study group 1995) and another report 
(Villar et al. 2005)  showed a slightly diminished risk of mortality and morbidity for 
segmental resection compared to subtotal colectomy. Long-term results between 
segmental resection and subtotal resection are better for segmental resection in 
terms of complications, bowel function, and QoL (You et al. 2008).
Laparoscopic approach for elective colon resections is widely accepted. In the 
short-term, laparoscopy provides shorter hospital stay, less postoperative pain and 
morbidity, shorter duration of postoperative ileus, and better QoL. Long-term results 
concerning morbidity, rates of cancer recurrences and mortality are similar between 
open and laparoscopic approaches (Guillou et al. 2005; Lacy et al. 1995; Lacy et al. 
2002; Weeks et al. 2002).  In acute CRO, laparoscopy is challenging, and somewhat 
contraindicated due to abdominal distension and fragility of the colon. Only a few 
studies have reported the utility of laparoscopy for the management of CRO. Some 
reports have suggested that laparoscopic approaches may be feasible in terms of 
shorter hospital stay and acceptable morbidity and mortality (Gash et al. 2011; Ng 
et al. 2006b; Ng et al. 2008).
2.2.2.2. Palliative surgery
Up to 25% of patients with CRC have synchronous metastases at the time of diagnosis 
(Ballantyne and Quin 1993; Manfredi et al. 2006), and only a minority of these 
patients is candidates for curative surgery. Improvement in oncologic therapy has 
increased the survival of these patients to 18 months (Poultsides et al. 2009). For 
CRC patients with synchronous metastases and absence of major symptoms, such 
as obstruction and bleeding, the issue of primary tumour resection followed by 
chemotherapy or immediate chemotherapy without tumour resection is controversial. 
Some have reported survival benefit for patients with good performance status 
undergoing resection of primary tumour followed by chemotherapy (Karoui et al. 
2011; Stillwell et al. 2010), and less complications from the primary tumour (Stillwell 
et al. 2010). Others have found no improvement in survival, but increased mortality 
and delay of chemotherapy initiation (Liu et al. 1997).
Palliative surgery becomes essential in the event of bowel obstruction. The aim 
of palliative surgery is to resolve obstruction and to improve QoL. In the case of 
palliative resection being impossible, stoma creation or entero-enterostomy may 
be the only options for palliative surgery. A multidisciplinary approach including 
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surgeon, oncologist, and pain control specialist is recommended in the treatment 
of incurable CRO (Ripamonti et al. 2008).
2.2.3 SELf-ExpANDING METAL STENTS IN MALIGNANT COLORECTAL 
OBSTRUCTION
2.2.3.1. Stenting technique and stent types
Stenting procedures can be performed under endoscopic and fluoroscopic control 
or using only fluoroscopic guidance. A combined endoscopic and fluoroscopic 
procedure is the most common technique (Sebastian et al. 2004). Procedures are 
usually performed under sedation and the stricture is approached with an endoscope. 
When approaching proximal strictures, a colonoscope is often needed. The site and 
length of the stricture can be measured by injecting water-soluble contrast media 
through the stricture, or by using a biliary balloon. Through-the-scope stents are 
smaller in diameter and can be passed over a guidewire and deployed through the 
working channel of a therapeutic endoscope. Larger diameter stents are deployed 
beside the scope using stiff guidewire. After SEMS deployment, the decompression 
of the bowel must be ensured. 
The characteristics for an ideal stent are similar for the upper and lower 
gastrointestinal tract, see page 19, second paragraph. As for GOO, SEMS used in 
CRO can be classified into two types, uncovered and covered. Uncovered stents are 
preferred over covered stents. In long-term follow-up, more complications, such 
as migration and loss of stent patency are associated with covered stents (Choi et 
al. 2013; Lee et al. 2007).
2.2.3.2. Overall outcome
SEMS was introduced as palliation of CRO in the year 1991, when it was used to 
decompress bowel obstruction caused by advanced rectal cancer (Dohmoto 1991). In 
1994, SEMS was used as a bridge to surgery in acute CRO (Tejero et al. 1994). Since 
then, SEMS have been increasingly used as a bridge to surgery for acute CRO and 
as palliation of malignant CRO. In two large pooled analyses consisting of patients 
stented as a bridge to surgery and as palliation, the overall technical success rate 
was between 92% and 94% and clinical success rate between 88% and 91% (Khot 
et al. 2002; Sebastian et al. 2004). In these large series, perforation rate was up to 
4%, migration rate between 10% and 12%, and stent reobstruction rate between 
7% and 10%. Minor complications such as bleeding and abdominal or rectal pain 
occurred in 5%. Mortality rate was low, only 1%. 
29
A meta-analysis, consisting of eight randomized studies involving both 
palliatively and preoperatively stented patients, found no difference in morbidity 
or mortality between stented and operated patients. For stented patients, primary 
anastomosis rates were higher and stoma rates lower than for operated patients 
(Cennamo et al. 2013).
2.2.3.3. Self-expanding metal stents as a bridge to surgery
The aim of SEMS placement in the event of acute CRO is to avoid emergency 
operations that carry higher morbidity and mortality rates than elective operations. 
Decompression of acute CRO with SEMS can allow patient stabilization and bowel 
preparation, tumour staging, and a subsequent elective resection. In prospective 
studies, technical success rates have ranged from 83% to 95% and clinical success 
rates from 77% to 95%. After stent placement, an elective operation was possible 
for 70% to 95% of the patients, and 77% to 88% of the patients could avoid a stoma 
(Alcantara et al. 2007; Brehant et al. 2009). In non-randomized comparative studies, 
stent placement before surgery has been associated with lower rates of colostomies, 
morbidity, and mortality than in emergency operations (Martinez-Santos et al. 
2002; Ng et al. 2006a). 
The results from randomized studies are somewhat controversial. According to 
reports, stent placement and subsequent surgery resulted in reduced morbidity, 
anastomotic leakages (Alcantara et al. 2011; Cheung et al. 2009), and stoma rate 
compared to the emergency surgery group (Cheung et al. 2009). In a Spanish study, 
no complications occurred in the SEMS group. A high rate of anastomotic leakages 
in the emergency surgery group led to a premature closure of the study (Alcantara 
et al. 2011). The most dangerous complication of SEMS placement is perforation. 
In addition to acute rise in mortality due to peritonitis, it may adversely affect the 
oncological outcome due to tumour spill. Two randomized multicentre studies on 
left-sided preoperative stenting versus emergency surgery were closed prematurely 
due to increase in complications in the SEMS arm (Pirlet et al. 2011; van Hooft et 
al. 2011). A lower technical success rate than average, 47% to 70%, was reported 
in those studies. Neither of the studies found differences in total morbidity, stoma 
rates, or mortality. Both studies reported high rates of overt (6% and 13%) and 
silent perforations (6% and 27%) in the stent groups (Pirlet et al. 2011; van Hooft 
et al. 2011). The effect of stent perforation on long-term oncological outcome is 
unclear. The data from non-randomized studies is heterogeneous, ranging from no 
difference between SEMS and emergency surgery to a reduced or increased survival 
for patients treated with preoperative stenting (Dastur et al. 2008;  Gianotti et al. 
2013;  Kim et al. 2013a;  Kim et al. 2009b;  Saida et al. 2003).
An ideal time from SEMS placement to surgery is unknown. The stent creates 
inflammation to surrounding tissues and may increase technical difficulties in 
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operation, as well as complications (Alcantara et al. 2007). Therefore, an elective 
operation should be performed promptly after SEMS placement. In randomized 
studies, patients underwent an operation mostly between 5 to 14 days and at latest 
within four weeks (Alcantara et al. 2011; Cheung et al. 2009; Pirlet et al. 2011; van 
Hooft et al. 2011). Elective operations can be performed either via laparotomy or 
laparoscopically (Cheung et al. 2009; Dulucq et al. 2006; Stipa et al. 2008).
2.2.3.4. Self-expanding metal stents as palliation
The data from non-comparative studies show technical success rates between 73% 
and 100%, clinical success rates between 62% and 96%, and total complication rates 
between 11% and 25% (Im et al. 2008; Law et al. 2004; Repici et al. 2007; Varpe et al. 
2008). Perforation rates have been 0% to 16%, migration rates 0% to 16%, and stent 
re-obstruction rates 0% to 16%. For palliatively stented patients, non-randomized 
comparative studies report shorter hospital stay, less acute complications, and similar 
survival to operated patients (Faragher et al. 2008; Ptok et al. 2006; Vemulapalli 
et al. 2010).
To date, three randomized studies have compared the results of palliative 
SEMS placement and surgery, and they provide inconsistent results (Fiori et al. 
2004a; Fiori et al. 2012; van Hooft et al. 2008; Xinopoulos et al. 2004). In an 
Italian study, SEMS was associated with shorter operative time, faster return to 
oral intake, shorter hospital stay, and similar short- and long-term complication 
rates and survival compared to the operative group (Fiori et al. 2004a; Fiori et al. 
2012). No perforations occurred in the Italian study. On the contrary, an unexpected 
high rate of perforations in the SEMS-arm led to a premature closure of another 
multicentre randomized study (van Hooft et al. 2008). 
For almost 85% of the patients who undergo SEMS placement for CRO, the 
etiology for obstruction is primary CRC (Sebastian et al. 2004). For CRC, the 
mechanism of obstruction is different from ECM, where the obstruction may develop 
from intracolonic invasion or metastasis or from extracolonic compression.  When 
CRO is caused by ECM, the bowel is often immobilized due to multiple strictures, 
carsinomatosis, and adhesions after previous surgery or radiation therapy making 
the stenting procedures potentially technically more difficult. The results on SEMS 
placement for obstruction caused by ECM are more inconsistent than for CRC 
etiology. Technical success rates vary between 42% and 95% and clinical success 
rates between 20% and 86% (Keswani et al. 2009; Kim et al. 2013b; Shin et al. 
2008; Trompetas et al. 2010). Results from comparative studies vary; some report 
lower clinical success rates and higher complication rates for ECM, while others 
find no difference in outcomes between CRC and ECM (Keswani et al. 2009; Kim 
et al. 2013b). 
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2.2.3.5. Long-term outcome and complication factors
For patients undergoing palliative stenting due to incurable malignancy, it is 
important to evaluate the long-term outcome of SEMS placement. The median 
stent patency has ranged between 90 days and 204 days (Im et al. 2008; Small et 
al. 2010; Suh et al. 2010).  The amount of patients remaining free of re-obstruction 
from stent placement to death has ranged from 77% to 88% (Manes et al. 2011; Small 
et al. 2010). The rate of long-term complications has been mostly between 11% 
and 24% (Jung et al. 2010; Small et al. 2010), but higher complication rates up 
to 51% have also been reported (Fernandez-Esparrach et al. 2010). A Karnofsky 
performance status of ≤ 50 is associated with shorter survival and almost 4 times 
higher risk of death within 6 months after the SEMS placement (Manes et al. 2011).
In stenting malignant CRO, male gender, complete obstruction, stent diameter 
≤ 22 mm, stricture dilation during SEMS insertion, and inexperienced endoscopist 
in pancreatobiliary endoscopy  are significant risk factors for complication (Small 
et al. 2010), as well as long length of the stricture (Jung et al. 2010; Manes et al. 
2011). The impact of etiology (CRC vs. ECM) and site of the stricture (proximal 
vs. distal) on outcome is unclear (Jung et al. 2010; Manes et al. 2011; Small et 
al. 2010). Risk factors for the most dangerous complication, perforation, include 
bevacizumab therapy and stricture dilation (Manes et al. 2011; Small et al. 2010). 
2.2.3.6. Quality of life and costs
Data on the impact of SEMS placement or surgery on symptoms or QoL in CRO 
are few.  In a prospective study of palliative stenting or stoma creation, Nagula et 
al. (Nagula et al. 2010), found that both treatment methods improved the CRO 
symptoms. SEMS placement was associated with improved overall QoL, however. In 
a Dutch randomized study comparing preoperative stenting and emergency surgery, 
the primary outcome measure was mean global health status measured by EORTC 
QLQ-C30. The authors found no difference in QoL and patient comfort between 
two study groups (van Hooft et al. 2011). In another report by an Italian group on 
palliative stenting versus colostomy, colostomy had a negative impact on patients’ 
and family members’ social life and daily activities (Fiori et al. 2012). The patients 
and family members scored the following parameters from 1 to 4: satisfaction 
with the procedure, lifestyle, acceptance of stoma, and abdominal symptoms. No 
standardized questionnaires were used.
Two randomized studies include cost analysis. Total costs were equal for 
palliatively stented or operated patients (Xinopoulos et al. 2004), as well as for 
bridge to surgery or emergency operation groups (Ho et al. 2012).
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2.2.4 MANAGEMENT Of BENIGN COLORECTAL OBSTRUCTION
2.2.4.1. Anastomotic stricture
An anastomotic stricture (AS) is defined by Luchtefeld et al. (Luchtefeld et al. 1989) 
as “chronic narrowing or obstruction to the flow of intestinal contents resulting in 
clinical signs or symptoms of either complete or partial obstruction.” In practice, 
AS is usually defined as a stenosis ≤12 mm, preventing the passage of a 12 mm 
sigmoideoscope. Risk factors for AS include: preoperative obesity, sepsis, radiation 
therapy, and incomplete doughnuts, and in the postoperative period anastomotic 
leakage, pelvic infection, and radiotherapy (Luchtefeld et al. 1989).
The initial treatment method for AS is dilation, which can be performed manually 
if the stricture is located distally. Endoscopic balloon dilation (EBD) is an effective 
technique for uncomplicated strictures with a stricture resolution rate of up to 
100% (Ambrosetti et al. 2008). Multiple dilatation sessions are often needed, 
however. Complications related to EBD include perforation (5%), abscess (2%), 
and recurrent stricture (10%) (Suchan et al. 2003). Long-term health-related QoL 
has been reported to be diminished after EBD due to gastrointestinal symptoms 
and stress by treatment (Nguyen-Tang et al. 2008). EBD is more likely to fail if 
stricture is irregular, kinked, fixed, and longer than 1 cm. A surgical resection is 
often needed to manage these complex strictures (Schlegel et al. 2001).
2.2.4.2. Diverticular stricture
A diverticular stricture (DS) develops from chronic inflammation due to recurrent 
diverticulitis. Bowel obstruction can occur acutely, demanding emergency 
management, or with chronic symptoms. The incidence of DS is 7% of all cases 
of diverticular disease (McConnell et al. 2003). A symptomatic DS, in particular 
with chronic symptoms and a possibility of underlying malignant etiology, is an 
indication for surgery (King et al. 1990; Klarenbeek et al. 2010). A laparoscopic 
resection with primary anastomosis can be performed with a low rate of morbidity 
in DS. For elective surgery of DS, conversion and stoma rates are higher and the 
length of hospital stay longer than for surgery of uncomplicated diverticulosis (Royds 
et al. 2012).
2.2.4.3. Crohn`s disease stricture
Strictures of the gastrointestinal tract are common complications of Crohn`s 
disease (CD), occurring in one third of patients within 10 years of diagnosis (Cosnes 
et al. 2002). The most common locations for strictures are the terminal ileum, 
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ileocolonic anastomosis, and colon (Landi et al. 1992). Clinically relevant strictures 
with prestenotic dilation and obstructive symptoms are usually treated surgically. 
Surgical options include resection and stricturoplasty. Morbidity rates associated 
with bowel resections and stricturoplasties are up to 35% and 23%, respectively 
(Bruewer et al. 2003; Fearnhead et al. 2006). In addition, reoperation rate due to new 
stricture or recurrence of stricture is between 15% and 45% within 5 years (Legnani 
and Kornbluth 2002; Tichansky et al. 2000). Since CD is surgically incurable chronic 
disease, multiple operations can lead into short bowel syndrome in the long term. 
EBD is an effective alternative for surgery with a clinical success rate of 90% to 
96%. The relapse rate of stricture is up to 46% within 6 years (Ajlouni et al. 2007; 
Stienecker et al. 2009). The reported perforation rate is less than 3% (Foster et al. 
2008; Stienecker et al. 2009). 
2.2.4.4. Self-expanding metal stents in benign colorectal obstruction
SEMS have been rarely used for benign CRO; only 3% of stenting procedures are 
due to benign etiology (Khot et al. 2002). The first case report on SEMS placement 
for benign rectal anastomotic stricture was published in the year 1997 (Salinas 
et al. 1997). In the same year, CD stricture was treated with an endoscopic stent 
placement (Matsuhashi et al. 1997). Since then, also DS (Davidson and Sweeney 
1998) and radiation stricture were managed with stenting (Yates and Baron 1999).
Stents have been used as a bridge to surgery in diverticulosis and CD, and as a 
definitive treatment in AS and in patients unfit for surgery. Data on SEMS placement 
for benign CRO consists mainly of case reports and small size series. No randomized 
studies on the use of SEMS for benign strictures exist. Although the technical success 
rate of stent placement in benign stricture is comparable with malignant etiology, 
a higher rate of complications is associated with benign etiology, ranging between 
23% and 71% (Dai et al. 2010; Pommergaard et al. 2009). Diverticular disease, 
in particular, is associated with a high incidence of complications (Forshaw et al. 
2006; Pommergaard et al. 2009). A reported rate of perforations in diverticular 
disease is up to 42%. Migration is more common in benign etiology due to absence 
of tumour ingrowth into the stent (Suzuki et al. 2004).
In a series of 23 patients, the indications for stenting were DS (n=16), AS 
(n=3), radiation stricture (n=3), and CD (n=1). Technical and clinical success 
rates were 100% and 95%, respectively. The long-term follow-up was available 
for 21 patients. Major complication occurred for 38% of the patients (perforation 
2, migration 2, reobstruction 4), and of these complications 87% occurred after 7 
days. An operation was performed for 19 patients, and of those, SEMS served as a 
bridge to surgery for 16 patients with a median time to surgery of 12 days (range 2 
days- 18 months). An emergency operation was performed for three patients due 
to perforation or reobstruction within 1 to 49 days of stenting. Despite of SEMS, a 
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stoma was constructed for 58% of the patients. The authors concluded that SEMS 
placement for benign etiology is associated with a high rate of late complications, 
and if an elective operation is planned it should be performed within 7 days of 
SEMS placement. (Small et al. 2008)
SEMS placement for AS has shown promising results. For 75% of the patients, 
the AS was resolved with SEMS allowing closure of defunctioning stomas (Forshaw 
et al. 2006). In another report, 50% of the strictures were resolved initially, but 
the long-term success was achieved for 36% during the follow-up period of a mean 
of 3 years (Dai et al. 2010). To date, the largest study of SEMS and benign CRO 
included 43 patients, of whom 40 were patients with AS (Vanbiervliet et al. 2013). 
The clinical success rate was 81%, but for 53% of the patients, the stricture recurred. 
The migration rate was 63%. In multivariate analysis, no predictive factors for 
clinical efficacy or recurrence were found.
The data on SEMS`s efficacy in Crohn`s stricture is variable. For selected 
patients, long term successful outcomes with a stent even up to nine years have 
been reported (Levine et al. 2012). At the same time, a prospective study with 11 CD 
patients showed an 18% major morbidity rate requiring surgery and a 70% migration 
rate. For only 1 of 11 (9%) patients, a planned stent removal was performed with 
no recurrence of obstructive symptoms; for the rest of the patients, the stricture 
recurred ultimately (Attar et al. 2012). To date, the largest study of SEMS and CD 
strictures includes 17 patients with 25 SEMS deployed (Loras et al. 2012). The 
stents were maintained in their place for a mean of 28 days. The authors reported 
64% success rate with a mean follow up period of 67 weeks. The recurrence rate 
of stricture was 43%, which led to additional endoscopic procedures or surgery. Of 
17 patients, 7 (42%) underwent operation eventually. The migration rate was 52% 
and no perforations occurred.
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3. AIMS OF THE STUDY
The aims of this present study were the following:
1. To study the efficacy and safety of SEMS as palliation of malignant GOO. To 
evaluate the feasibility of combined endoscopic stenting of malignant biliary 
and duodenal obstruction. 
2. To study advanced primary gastric cancer and GOO. To compare the results 
of stent placement, PR, and GJ as palliation of GOO due to advanced primary 
gastric cancer.
3. To study the utility of SEMS in benign CRO. 
4. To evaluate the efficacy and safety of SEMS as bridge to surgery and as palliation 
in malignant CRO. To compare the results of stent placement as palliation for 
CRC and ECM.
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4. PATIENTS AND METHODS
4.1 pATIENTS
All the patients (n=323) were treated at Meilahti Hospital, part of Helsinki University 
Central Hospital between January 1998 and December 2010. The patients who 
underwent SEMS placement were identified from the endoscopy unit’s database. 
For study II, surgically treated patients were identified from the surgical unit`s 
database. For all studies, the data were recorded in a structured template and the 
results were analyzed retrospectively. The study was approved by the Institutional 
Review Board of Department of Surgery, Helsinki University Central Hospital.
Patients (n=104) who underwent enteral stent placement for malignant, 
noncurable GOO between January 1999 and May 2007 were included in study I. 
Patients (n=97) who underwent palliative resection (PR), open gastrojejunostomy 
(GJ), or endoscopic stenting (ES) for GOO caused by advanced, primary gastric 
cancer between January 1999 and December 2010 were included in study II. Of 
the stented gastric cancer patients, 24 were included in both study I and II. The 
patients were followed until their death (I, II) or the study end point (December 
2011) (II). Occurrence and treatment of biliary obstruction were also recorded. The 
clinical characteristics of the patients in study I are presented in Table 2. In study 
II, gastric cancer was defined as advanced in cases with distant metastases, with 
invasion to adjacent organs and radical operation (R0) being impossible, or with 
unresectable lymph node metastases. Palliative total gastrectomies were excluded 
from the study. An accurate TNM stage for ES and GJ groups was unavailable; 
therefore a comparison of M stage between three groups was based on radiology, 
surgery, and histology. For the PR group, the distribution of T stage was: T3 17 
patients (65%), T4 6 patients (23%), and Tx 3 patients (12%). For the GJ group 
the distribution of T stage was: T3 2 patients (10%), T4 9 patients (43%), and Tx 
10 patients (48%). Re-admissions to hospital with symptoms of re-obstruction, but 
without radiologic or endoscopic confirmation, were obtained from the medical 
records. Between the three groups, the distributions of histology (p= 0.152), site 
of obstruction (p= 0.202), and M-stage (p= 0.478) were similar. From baseline 
characteristics, pre-procedure albumin levels, WHO scores, and pre-procedure 
GOOSS were statistically different between the groups (Table 3). Distributions of 
ASA grades (p= 0.133), BMIs (p= 0.083), and CCIs (p= 0.785) were similar between 
the groups.
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Table 2. Clinical characteristics of 104 patients with malignant gastric outlet 
obstruction (I)
NO. OF PATIENTS 104
sex ratio, m/W (%) 43/61 (41/59)
Age, median (range) 72 (40-89)
tumour origin, n (%)
    Pancreatic 51 (49)
    Gastric 24 (23)
    duodenal 7 (7)
    Biliary 5 (5)
    other malignancies 17 (16)
site of obstruction, n (%)
    Antrum/pylorus 21 (20)
    d1 23 (22)
    d2 35 (34)
    d3 23 (22)
    d4 2 (2)
Follow-up, days, median (range) 62 (1-933)
 
m/W, men/women; d1, first part of duodenum; d2, second part of duodenum; d3, third part of 
duodenum; d4, fourth part of duodenum
Table 3. Clinical characteristics of 97 patients with gastric cancer and gastric outlet 
obstruction (II)
ES PR GJ P
no. of patients 50 26 21
Age, median (range) 73 (40-94) 70 (33-92) 69 (31-88) 0.155
sex ratio (m:W) 24:26 17:9 10:11 0.311
Albumin g/l, median (range) 25.0 (16.1-43.0) 33.1 (23.8-47.0) 30.3 (19.7-42.4) <0.001
WHo score 0.001
  i 17 22 12
  ii 12 4 7
  iii 15 0 2
  iV 2 0 0
Pre-procedure Gooss <0.001
  0 = no oral intake 38 9 10
  1 = Liquids only 10 10 2
  2 = soft solids 2 6 6
  3 = Low-residue or full diet 0 1 3
 
es, endoscopic stenting; Pr, palliative resection; GJ, gastrojejunostomy; m/W, men/women; 
Gooss, gastric outlet obstruction scoring system
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PATIENTS AND METHODS
Patients (n=21) who underwent colorectal stent placement for benign CRO 
between January 1998 and December 2008 were included in study III. The patients 
were followed until their death or study end point (September 2009), or until a 
complication demanding surgical intervention after stent placement occurred. 
The etiologies for strictures included anastomotic strictures after prior colorectal 
surgery (eight patients), DS (ten patients), stricture after radiation therapy (one 
patient), and anastomotic strictures and CD (two patients). The patients (n=101) 
who underwent colorectal stent placement for malignant CRO between January 
1998 and December 2009 were included in study IV. The patients underwent SEMS 
placement either as a bridge to surgery or as palliation. The patients were followed 
until definitive operation after stenting, until a complication demanding surgical 
intervention after stenting, until the study end point (November 2010), or until their 
death. The strictures had developed on the basis of CRC (77 patients) or ECM (24 
patients). The tumour origins for ECM were the following: gynecologic 7, breast 6, 
pancreas 3, prostate 3, stomach 3, bladder 1, small bowel neuroendocrine 1. For 
palliatively stented patients, preprocedure body mass index (BMI), American Society 
of Anesthesiologists (ASA) grade, and Charlson Comorbidity Index (CCI) (Charlson 
et al. 1987) were recorded.  Of preprocedure patient characteristics, median age (p= 
0.162), BMI (p=0.052), and ASA grade (p= 0.381) were statistically similar between 
the two palliative groups. In palliation groups, women were the majority in the ECM 
group (CRC: 43/23 vs. ECM 8/16, p= 0.007). Median CCIs were higher in the CRC 
group. The patient characteristics in studies III and IV are presented in Table 4.
Table 4. Clinical characteristics of 21 patients with benign and 101 patients with 
malignant colorectal obstruction (III and IV)
BENIGN CRO (III) MALIGNANT CRO (IV)
no. of patients 21 101
sex ratio, m/W (%) 9/12 (43/57) 58/43 (57/43)
Age, median (range) 64 (34-89) 66 (36-98)
degree of obstruction
 total 16 55
 subtotal 5 42
site of obstruction
 sigmoid colon 15 45
 rectum 4 42
 transverse colon 0 7
 descending colon 1 6
 Hepatic flexure 0 1
 ileorectal anastomosis 1 0
Follow-up, days, median (range) 137 (2-2250) 91 (0-1035)
 
cro, colorectal obstruction; m/W, men/women
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4.2 DIAGNOSIS AND DEfINITIONS
For GOO, the location of the obstruction was limited from the corpus of the stomach 
to the fourth part of the duodenum (I, II). The diagnosis of GOO was based on clinical 
examination and symptoms of the patient, endoscopic findings, and radiologic 
examinations (plain x-ray of the abdomen, oral contrast meal study, CT) (I, II). 
The information of pre- and post-procedural oral intake was obtained from medical 
records, including also nurses’ notes for each day during the hospital stay. The 
diagnosis of CRO was based on clinical and radiological examinations (plain x-ray 
of the abdomen, barium enema, CT, MRI), or endoscopic findings prior to SEMS 
placement (III, IV). 
In all studies, the definition of technical success of stenting was successful stent 
placement and deployment to the stricture site. In upper-GI stenting, clinical success 
was defined as the ability to tolerate at least liquid food (I, II). In colorectal stenting, 
a definition of clinical success was effective decompression and symptom relief 
within 72 h of stent placement without endoscopic or surgical reinterventions (III, 
IV). Clinical success rate was calculated as a percentage relative to all patients 
(intention to treat analysis). Complications were classified into early (within 7 days 
after stenting) and late (after 7 days of stenting) complications (III, IV). In benign 
colorectal stenting, the complications were divided into major (perforation) and 
minor (migration, abscess, colovesical fistula) complications (III). In II,	symptom-
free survival was defined as a time interval from the first stenting or operation to 
recurrent GOO causing re-intervention, or to study end point, or to patient`s death.
In all studies, if the patient underwent multiple procedures, only the first one 
was used in the analysis.
4.3 SCORING SySTEMS
The gastric outlet obstruction scoring system (Adler and Baron 2002) (Table 1) 
was used to assess tolerance of oral intake before and after stenting (I, II).  For 
assessing the patients‘clinical condition and comorbidities, the American Society 
of Anesthesiologists (ASA) grade (II, III, IV), Charlson comorbidity index (CCI) 
(Charlson et al. 1987) (II, IV), and WHO score (Oken et al. 1982) (Table 5) (II) 
were used. 
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Table 5. WHO score
0 Asymptomatic (Fully active, able to carry on all predisease activities without restriction)
1
symptomatic but completely ambulatory (restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or sedentary nature. For example, light 
housework, office work)
2 symptomatic, <50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours)
3 symptomatic, >50% in bed, but not bedbound (capable of only limited self-care, confined to bed or chair 50% or more of waking hours)
4 Bedbound (completely disabled. cannot carry on any self-care. totally confined to bed or chair)
5 death
4.4 STENTING TECHNIQUES
4.4.1 STENT pLACEMENT fOR MALIGNANT GASTRIC OUTLET OBSTRUCTION
The procedures were performed under monitored anesthesia and intravenous 
sedation with the patient in a prone position. A therapeutic gastroscope or 
duodenoscope was used for SEMS placement. The majority of procedures were 
performed by using gastroscope, but for strictures located in the third or fourth 
part of the duodenum, a large-channel duodenoscope was used if needed. When 
the stricture site had been approached with a scope, a long guidewire was passed 
beyond the stricture. Contrast media was often injected to verify the location and 
length of the stricture. When necessary, an 18-mm biliary balloon was used for 
definition of the exact site and length of the stricture. Then, a stent delivery system 
was inserted through the scope and SEMS was deployed under endoscopic and 
fluoroscopic control (Figure 4). A dilatation of the stent was carried out, if necessary. 
The stents used for palliation of GOO included Wallstent®, Wallflex® (Boston 
Scientific, Natick, MA, USA), and Hanarostent® (M.I.Tech, Seoul, Korea). The 
majority of the stents were either Wallstent® or Wallflex®. For combined biliary 
and duodenal stenting, a self-expanding metal biliary stent was inserted before the 
duodenal stent was deployed.
4.4.2 STENT pLACEMENT fOR COLORECTAL OBSTRUCTION
The procedures were performed under intravenous sedation. The site of obstruction 
was approached by using a colonoscope, sigmoideoscope, or therapeutic upper 
endoscope, as appropriate. A 200-cm, triple-lumen, 18-mm biliary balloon 
(Endoflex® extraction balloon, Voerde, Germany) and 0.035-in 450 cm guidewire 
(Jagwire®, Boston Scientific, Miami, Fl, USA) was passed beyond the stricture to 
the proximal colon under endoscopic and fluoroscopic control. A contrast was often 
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injected to verify the site and length of the stricture and positioning of the wire above 
the obstruction. The 18-mm balloon was also used in order to measure the length of 
the stricture. Usually, the stricture was marked out with radiopaque markers. When 
deploying through-the-scope stents, a regular guide wire (Jagwire®) was used, 
but with stents deployed beside the endoscope, a stiff 0.035-in 300 cm guidewire 
(Back-Up Meier®, Boston Scientific, Natick MA, USA) was used. Dilations of the 
strictures or stents were not routinely performed but, when necessary, dilations 
were carried out to 15–18 mm with a 240 cm through- the- scope balloon catheter 
(CRE® wire-guided, Boston Scientific, Natick, MA, USA) (Figure 5).
Stents used for malignant CRO included Memotherm® (Bard, Angiomed, 
Karlsruhe, Germany), Ultraflex®, Ultraflex Precision®, Wallflex®, Wallstent® 
(Boston Scientific, Natick, MA, USA), Choo® (M.I.Tech, Seoul, Korea), Instent® 
and Bard® (Olympus Corporation, Tokyo, Japan). For malignant CRO, the majority 
of the stents deployed included Ultraflex Precision® (n=43) or Wallflex® (n=34). 
For stenting benign CRO, Hanarostent® (M.I.Tech, Seoul, Korea), Memotherm® 
(Bard, Angiomed, Karlsruhe, Germany), Ultraflex®, Ultraflex Precision®, 
Wallflex®, Wallstent®, and Polyflex® (Boston Scientific, Natick, MA, USA) were 
used. The majority of the stents deployed included Hanarostent® (n=10), Wallflex® 
(n=5), and Ultraflex Precision® (n=4).
An uncovered stent was deployed through the working channel of the scope 
(Wallflex®, Wallstent®) or beside the endoscope (Ultraflex Precision®). The 
covered stents were deployed beside the scope (Hanarostent®, Polyflex®). Both 
uncovered and covered stents were deployed under endoscopic and fluoroscopic 
control. In benign CRO, a scheduled removal of the covered stent was planned unless 
a spontaneous migration had occurred indicating successful dilation of the stricture.
figure 4. An uncovered stent is deployed under endoscopic and fluoroscopic control
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4.5 SURGICAL TREATMENT
In II, all operations were started with an intention to perform a resection. Based 
on laparotomy findings, a surgeon made the decision of whether to perform a 
palliative resection or gastrojejunostomy. All operations were performed through 
upper midline or rooftop laparotomy incision. The patients who were operated on 
underwent either gastric resection with Billroth II- or Roux-en-Y-reconstruction, 
or retro- or antecolic gastrojejunostomy.
4.6 STATISTICAL ANALySIS
All the statistical analyses were performed by using SPSS (Statistical Package for 
the Social Sciences) for Windows (SPSS inc., Chicago, IL, USA). Values of p <0.05 
were considered statistically significant.
Categorical variables were reported as frequencies and percentages. Comparison 
of categorical variables was performed by using x2 test or Fisher’s exact test, as 
appropriate. Continuous variables were reported as medians and ranges and were 
compared by using Mann-Whitney U test. Comparison of continuous variables 
between three groups was performed by using Kruskal-Wallis test (II). Wilcoxon 
signed rank test was used for the analysis of difference between the dysphagia 
scores before and after stent placement (I). Kaplan-Meier life-tables were calculated 
and for assessing the significance of the difference between survivals of the groups 
the log rank test was used (II). A Cox proportional hazards model was used for 
multivariate survival analysis (II).
figure 5. CRO caused by colon tumour has been released with an uncovered SEMS
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5. RESULTS
5.1 STENTING MALIGNANT GASTRIC OUTLET  
OBSTRUCTION (I)
Overall results
A total of 104 patients with 130 stenting procedures were included in the analysis. 
Technical success was achieved for 100% and clinical success for 93% of the patients 
(Table 6).  One patient received two stents into two different stricture sites in a single 
session. Chemotherapy was administered for 31 (30%) patients before stenting, and 
21 (20%) patients could start or continue chemotherapy after stenting. A median 
GOOSS after stent placement was 2, and the dysphagia scores improved significantly 
after stenting (p< 0.001). Of 104 patients, 76 (73%) managed until death with one 
stenting procedure, and the median survival time for them was 56 days (9-933). 
Immediate failure occurred in ten procedures for nine patients, and three of them 
occurred after the first stenting. The failures included three perforations, six kinkings 
of stent, and one abscess with sepsis. Complications occurred for 13 patients (12.5%). 
Complications included five kinkings of stent, three perforations, and abscess with 
sepsis, pulmonary embolism, aspiration pneumonia, brain stroke, and cholangitis 1 
patient each. Four patients underwent operation, and of those three patients due to 
persistent obstruction. One patient was operated on due to a suspicion of perforation 
on abdominal X-ray, but no perforation was found in laparotomy. Three patients 
died of technical complications (perforation two patients, abscess with sepsis one 
patient), and three died of procedure-related complications (pulmonary embolism, 
aspiration pneumonia, stroke one patient each). Procedure-related mortality was 
5.8% (6/104). The overall 30 day mortality rate was 28.8% (30/104).
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RESULTS
Table 6. procedure details and overall outcome for 104 patients with gastric outlet 
obstruction (I)
technical success % 100
clinical success % 93
Procedure details
 Length of stricture, cm* 3 (1-6)
 Length of stent, cm* 6 (6-12)
 Procedure time, min* 30 (10-90)
Pre-procedure Gooss, n (%)
 0= no oral intake 92 (88.5)
 1= Liquids only 12 (11.5)
Post-procedure Gooss, n (%)
 0= no oral intake 7 (6.7)
 1= Liquids only 23 (22.1)
 2= soft solids 60 (57.7)
 3= Low-residue or full diet 12 (11.5)
Hospital stay, days* 3 (1-26)
survival, days* 62 (1-933)
*median (range); Gooss, gastric outlet obstruction scoring system
Repeated stenting
Repeated stenting became necessary for 21 patients (20.2%). Two patients were 
stented immediately due to kinking of first stent and failure to decompress. Those 
patients had a perforation and died. The remaining 19 patients underwent a second 
procedure because of re-obstruction after a median of 93 days (range 8-282) of the 
primary procedure. Of 19 patients, three patients failed to decompress, one had an 
abscess with septicemia leading to death, and one had perforation which also led to 
death. Of three patients who failed to decompress, two underwent an operation and 
one underwent a third stenting. The median survival time for 19 re-stented patients 
was 265 days (range 20-734), which was significantly longer than for patients who 
underwent only one stenting procedure (p< 0.001). 
Of 104 patients, four (3.8%) were stented thrice after a median of 136 days 
(range 90-146) of the second procedure. For one patient, stent placement became 
necessary four times.
Gastric outlet obstruction and biliary obstruction
A total of 56 (53.8%) patients had biliary obstruction. In 46 patients, the biliary 
obstruction occurred before the enteral stent placement, and for them biliary 
obstruction had been treated with plastic (n=16) or metallic (n=25) stent or with 
PTD (n=5). Concomitant biliary and enteral obstruction occurred in 11 (10.6%) 
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patients. For nine patients, biliary obstruction had been treated with a stent (8 
plastic, 1 metallic) previously. Combined stenting was successful in 10/11 (91%) 
patients. One patient underwent PTD.
None of the combined stent placement patients had recurrent biliary obstruction 
during the follow-up. After enteral stenting, biliary obstruction developed in 15 
patients (14.4%), and seven of them had a previous biliary stent (2 plastic, 3 metallic, 
2 PTD). Of 15 patients, six (40%) underwent successful ERC and SEMS placement 
and six underwent PTD. No intervention was possible for three patients due to 
their poor clinical status.
5.2 pALLIATION Of GASTRIC OUTLET OBSTRUCTION IN 
GASTRIC CANCER (II)
Overall results
There was no difference in clinical success rates (ES 88% vs. PR 100% vs. GJ 81%, 
p=0.057) among three groups. The tolerance of liquid and soft solid diet was faster 
for stented patients than for operated patients (Table 7). For operated patients, 
the hospital stay was longer than for patients who underwent SEMS placement. 
The differences in re-admission rates to hospital were insignificant (ES 16% vs. PR 
12% vs. GJ 19%, p=0.770) between the groups. The number of patients receiving 
chemotherapy after treatment (ES 22% vs. PR 46% vs. GJ 29%, p=0.078) and the 
occurrence of biliary obstruction (ES 8% vs. PR 19% vs. GJ 14%, p=0.353) were 
highest for the PR group but the differences were not statistically significant between 
three palliation groups. The biliary obstruction was managed mainly by ERC and 
metallic stent placement or PTC (ES: ERC 3 patients, cholecystojejunostomy 1 
patient; PR: PTC 3 patients, conservative 2 patients; GJ: combined PTC and ERC 
1 patient, PTC 1 patient, conservative 1 patient).
In univariate survival analysis, the differences in symptom-free survival 
(p=0.004) and overall survival (p=0.003) were significant between the groups, and 
for the PR group both symptom-free and overall survivals were longest. Multivariate 
survival analysis identified patient’s age, BMI, pre-procedure GOOSS, treatment 
modality, and chemotherapy as independent prognostic factors (Table 8). ASA 
grade, WHO score, albumin level, and sex were found to be insignificant factors.
Complications, re-interventions, and mortality
Of 13 complications in the ES group, 12 were re-obstructions and one was bleeding. 
Five of the reobstructed patients underwent re-stenting once, one patient twice, and 
one patient had two re-stentings and an operation due to persistent obstruction. 
For one patient, stent dilation and afterwards an operation became necessary due 
to recurrent re-obstruction. The four remaining patients with re-obstruction were 
treated conservatively due to poor clinical status. A perforation occurred for a 
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restented patient, and it was treated conservatively due to the poor clinical status 
of the patient.
In the PR group, two patients with re-obstructions and one patient with an abscess 
underwent operation. Three patients with re-obstruction underwent re-stenting 
but obstruction persisted in two of them. One patient underwent two endoscopic 
procedures and the other three endoscopic procedures and an operation. For one 
patient, an abscess was drained percutaneously, and afterwards re-obstruction was 
treated with a stent. Two remaining complications in the PR group, one bleeding 
and one re-obstruction, were treated conservatively due to the poor clinical status 
of the patients.
In the GJ group, both complications were re-obstructions. Treatment of 
obstruction was conservative for one patient due to poor general health. The other 
patient was operated on twice.
The overall mortality rate within 30 days was 18.6% (12/50 ES, 1/26 PR, 5/21 GJ). 
For one patient, the cause of death was perforation and peritonitis after duodenal 
stent placement; the remaining six patients died of advanced gastric cancer.
Table 7. Outcome data for patients with gastric outlet obstruction in gastric cancer (II)
ES PR GJ P
time to free liquids (Gooss 1), days* 0 (0-4) 3 (2-4) 2 (1-9) <0.001
time to soft solids (Gooss 2), days* 1 (0-7) 4 (3-11) 4 (3-10) <0.001
Hospital stay, days* 3 (0-28) 9 (3-15) 8 (4-27) <0.001
complications n (%) 13 (26) 9 (35) 2 (10) 0.134
 re-obstruction 12 6 2
 Abscess 0 2 0
 Bleeding 1 1 0
time to complication, days* 95 (5-304) 183 (10-908) 40 (18-61) 0.202
discharge from hospital 0.001
 Home 24 24 11
 other hospital or hospice 22 2 7
 Hospital death 4 0 3
symptom-free survival, days* 43 (1-453) 223 (25-2784) 121 (11-656) <0.001
survival, days* 50 (1-453) 241 (25-2784) 141 (11-656) <0.001
es, endoscopic stenting; Pr, palliative resection; GJ, gastrojejunostomy; Gooss, gastric outlet 
scoring system; *median (range)
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Table 8. Multivariate survival analysis in gastric cancer (II)
Wald P HR 95% CI
treatment group
 es 17.093 <0.001
 Pr 16.943 <0.001 0.246 0.126-0.479
 GJ 1.700 0.192 0.611 0.291-1.282
Age 6.092 0.014 0.980 0.965-0.996
Pre-procedure Gooss
 0 = no oral intake 8.987 0.029
 1 = Liquids only 1.869 0.172 1.504 0.838-2.701
 2 = soft solids 1.479 0.224 0.625 0.293-1.334
 3 = Low-residue or full diet 4.568 0.033 0.228 0.059-0.884
Bmi 6.064 0.014 1.082 1.016-1.153
Post-procedure chemotherapy 45.738 <0.001 0.073 0.034-0.156
Hr, hazard ratio; 95% ci, 95% confidence interval; es, endoscopic stenting; Pr, palliative resection; 
GJ, gastrojejunostomy; Gooss, gastric outlet scoring system; Bmi, body mass index
5.3 STENTING BENIGN AND MALIGNANT COLORECTAL 
OBSTRUCTION (III AND IV)
Overall results
A total of 122 patients with 131 stenting procedures were included in the analysis. 
Of the patients, 21 patients with 23 stenting procedures underwent stent placement 
due to benign etiology (III) and 101 patients with 108 stenting procedures due 
to malignant etiology (IV). Overall technical and clinical success rates were 99% 
(121/122) and 85% (104/122), respectively. A loop-colostomy was performed for 
the patient with technical failure. Two co-axial stents were inserted in a single 
session for two patients with benign CRO and for four patients with malignant 
CRO. After treatment in our unit, seven patients with benign CRO and 38 patients 
with malignant CRO were transferred to other hospitals, and for these patients the 
total inpatient time was unavailable. Procedure details for studies III and IV are 
presented in Table 9.
Of 21 patients stented for benign CRO (III), 9 (43%) had a complication in 
10 of 23 procedures. Of the complications, six were major (perforation n=6) and 
four were minor (abscess n=2, migration n=1, fistula n=1). Of the complications, 
three occurred early, within a week, and seven occurred late. No procedure-related 
mortality occurred. The patient characteristics, complications, and patient outcomes 
are presented in Table 10. 
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Of 101 patients stented for malignant CRO (IV), for 23 (23%) chemotherapy 
was administered before stenting and 46 (46%) patients could start or continue 
chemotherapy after stent placement. The complication rate was 20% (20 patients in 
22 procedures), and the median time to complication was 81.5 days (range 0-561). 
The majority of 22 complications occurred late; only three perforations occurred 
early, within a week of the procedure. Stent placement related mortality was 2% 
(2/101). At the end point of the study, seven patients were alive.
Table 9. procedure details for patients stented for benign and malignant colorectal 
obstruction (III and IV)
BENIGN CRO MALIGNANT CRO
technical success, n (%) 21/21 (100) 100/101 (99)
clinical success, n (%) 16/21 (76) 88/101 (87)
Length of stenosis, cm* 4.5 (2-8) 5 (1-12)
Length of stent, cm* 9 (6-12) 9 (6-12)
reported procedure time, 
min* 45 (10-100) 30 (10-145)
Hospital stay, days* 3 (1-60) 1 (1-20)
cro, colorectal obstruction; * median (range)
Anastomotic strictures (III)
For patients with AS, the initial indication for surgery had been CRC (n=4), 
diverticular disease (n=2), ovarian cancer (n=1) and obstipation (n=1). Of eight 
patients with AS, five (63%) were successfully treated with SEMS. For three 
patients, the stricture recurred after the discharge of SEMS. One patient underwent 
laparoscopic anastomosis resection four months after the SEMS discharge. The other 
patient underwent eventually three stenting procedures due to recurrent stricture, of 
which the last one resulted in a perforation and a surgery with permanent colostomy 
nine months after the first SEMS placement. The third patient with unsuccessful 
outcome underwent operation with colectomy and ileostomy due to perforation 
four months after stenting. The patients with perforations were even prior to SEMS 
treatment complicated cases with histories of anastomotic leakages and abscesses, 
and with strong refusal of permanent stoma. Stents migrated in three patients. One 
patient with immediate migration and failure to decompress underwent restenting. 
In two patients, the stent discharged spontaneously after 6 and 14 days, but the 
strictures were resolved.
Diverticular and radiation strictures (III)
The patient with radiation stricture had an uneventful recovery. For five DS patients, 
the indication of SEMS placement was a bridge to surgery. The five remaining 
patients were considered unsuitable for surgery due to poor clinical status, high age, 
and/or obesity. Four clinical failures occurred after SEMS placement for diverticular 
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strictures. Two of them were treated successfully with dilatation of the stent and 
with a decompression tube. Two patients required surgical treatment, both two days 
after stenting, and a permanent stoma was constructed for one of them. Perforation 
occurred in three preoperatively stented patients after 3, 5, and 67 days of stent 
placement. All underwent surgery, and Hartmann`s operation with permanent 
stoma was performed for two of them. Two minor late complications occurred. 
One patient with colovesical fistula due to penetration of the stent was treated 
with sigmoid resection 73 days after stenting. This particular patient had been 
waiting for an elective sigmoid resection. The other patient developed an abscess 
and underwent Hartmann`s operation with permanent stoma construction 14 days 
after stenting. Eventually, 70% of the DS patients were operated on.
Anastomotic strictures in Crohn`s disease (III)
Both patients had a history of long-lasting CD with numerous operations, and were 
highly selected cases for endoscopic stenting. For one patient, the indication for 
SEMS placement was an attempt to postpone the operation due to the patient`s 
poor clinical status. The stent`s efficacy for symptoms was inadequate, but the 
surgery could still be postponed by one month. Bowel resection with stent removal 
was performed 42 days after SEMS placement. The other patient refused stoma and 
surgery. AS stricture was stented with an uncovered stent. The patient underwent 
operation due to perforation 51 months after stenting.
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Bridge to surgery in colorectal cancer (IV)
For 11 patients, SEMS served as a bridge to surgery. Technical and clinical success 
was achieved for every patient. Among 11 patients, four had Dukes D cancer and 
those patients were considered operable after favorable outcome in oncologic 
treatment. An elective operation was performed after a median of 51 days (range 
17-453) of SEMS placement with a primary anastomosis rate of 90% (9/10). A 
Hartmann`s procedure was performed for one patient. For three patients with 
rectal cancer, a defunctioning loop stoma was performed.
Complication occurred for two patients. One patient underwent emergency 
operation with primary anastomosis due to early perforation; for the other patient, 
late recurrent obstruction was treated with a dilatation of the stent. Four (36%) 
patients were alive at the end point of the study. A median survival was 1284 days 
(range 255-2346).
Palliation of malignant colorectal obstruction (IV)
The palliation group consisted of 66 (69 procedures) CRC patients and 24 (28 
procedures) ECM patients. The procedure details and patient outcomes are presented 
in Table 11. Of complications, all perforations were operated on. For all patients, 
excluding one in the ECM group, a permanent colostomy (n=2) or loop-colostomy 
(n=2) was performed. Two patients in each palliation group underwent operation 
with loop-colostomy due to recurrent obstruction. In the CRC group, one stent 
migration resulted in Hartmann`s procedure and one fistula was managed by loop-
colostomy. All the remaining complications were managed either endoscopically or 
conservatively. Two perforations in the CRC group occurred early; the remaining 
complications occurred late.
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Table 11. procedure details, complications, and clinical outcomes for patients stented 
as palliation for malignant colorectal obstruction (IV)
CRC, PALLIATION ECM, PALLIATION P
no. of patients 66 24
technical success, n (%) 66 (100) 23 (96) ns
clinical success, n (%) 62 (94) 15 (63) <0.001
Procedure time, minutes, median (range) 30 (10-145) 45 (10-95) 0.021
stricture length, cm, median (range) 4 (1-12) 5.50 (2-12) 0.064
Hospital stay, days, median (range) 1 (1-20) 2.5 (1-20) 0.314
complication*, n (%) 13 (20) 7 (29) 0.497
 Perforation 3 2
 recurrent obstruction 4 3
 migration 3 1
 Fistula 1 0
 Abscess 1 0
 Hematoma 1 0
 Pain 0 1
operation*, n (%) 7 (11) 4 (17) 0.535
stoma*, n (%) 7 (11) 3 (13) 0.907
time to complication, days, median (range) 114 (0-561) 23 (10-218) 0.218
Follow-up, days, median (range) 131 (0-1035) 23 (0-643) <0.001
survival, days, median (range) 158 (4-1035) 49 (0-1460) 0.030
crc, colorectal cancer; ecm, extracolonic malignancies; *after all endoscopic procedures
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6. DISCUSSION
6.1 MANAGEMENT Of MALIGNANT GASTRIC OUTLET 
OBSTRUCTION (I, II)
For patients with incurable malignancies, GOO is a preterminal event. Frequently, 
the degradation of oral intake has lasted for some time before the diagnosis of 
incurable malignancy is made. Therefore, at the time of diagnosis it is common 
that the patients suffering from symptoms of GOO are in poor clinical condition, 
and when considering treatment options, they are also poor candidates for surgery. 
For these patients, the main goal of treatment is adequate symptom relief and 
preservation of reasonable quality of life. 
As shown by previous studies, endoscopic stent placement provides good 
palliation in GOO with rapid improvement in oral intake, short hospital stay, and 
acceptable rate of complications (Adler and Baron 2002; Holt et al. 2004; van 
Hooft et al. 2009). Our results on the efficacy of SEMS placement for malignant 
GOO are consistent with previous data. After SEMS placement, tolerance of oral 
intake increased markedly, from a median GOOSS 0 to 2. For 73% of the patients, 
one SEMS placement was sufficient treatment until death. Our comparative study 
of ES, GJ, and PR as palliation of GOO in advanced gastric cancer showed faster 
improvement of oral intake and shorter hospital stay for the ES group than for 
surgically treated patients.
Choosing the right treatment for each patient with GOO and limited survival is an 
important issue. The majority of the current data on palliation of GOO favors SEMS 
over GJ due to faster symptom relief and shorter hospital stay. SEMS placement 
carries a complication rate of about 20%, and even though most complications are 
minor and can be managed with additional stent placement, complications limit 
the value of SEMS placement in the treatment of GOO. Short-term outcome has 
been shown to be better for ES, but long-term outcome in terms of complications, 
food intake, and re-interventions is better for GJ, and it has been suggested that 
GJ should be a preferred treatment for patients whose expected survival is over 2 
months (Jeurnink et al. 2010). In addition to ES and GJ, for GOO caused by gastric 
cancer, the treatment options include also palliative resection. 
Previous reports have shown that patient’s pain, use of opioids, and WHO score 
predict survival (Jeurnink et al. 2011; van Hooft et al. 2010). In gastric cancer, 
intensity of preoperative symptoms correlates with prognosis which is poorest in 
patients with major symptoms such as GOO (Kahlke et al. 2004). Our study on 
GOO in gastric cancer shows similar results on the effect of symptoms and patient`s 
general condition on survival. In multivariate analysis, independent prognostic 
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factors were GOOSS and BMI which indicate patient`s symptoms, nutritional status, 
and clinical condition. In the ES group, pre- procedure albumin levels, BMIs, and 
oral intakes were lowest, and WHO scores poorest. For ES group, survival was 
also shortest. 
In multivariate analysis, in addition to GOOSS and BMI, PR as a treatment 
modality, patients young age, and chemotherapy were independent predictive 
factors for survival. Chemotherapy is a known predictive factor for better survival in 
advanced gastric cancer (Murad et al. 1993; Pyrhonen et al. 1995), but the influence of 
resection on survival in advanced gastric cancer has been unclear (Haugstvedt et al. 
1989; Kokkola et al. 2012). The survival for the PR group was longest, but the patients 
who underwent resection were healthier than stented patients. Interestingly, in a 
subgroup analysis, pre-operative clinical characteristics were similar for GJ and PR 
groups, as well as the number of patients who received post-operative chemotherapy 
indicating survival benefit after PR. 
Biliary obstruction developed for about half of the patients with incurable 
GOO. Our results on combined enteral and biliary stenting are in concordance 
with previous studies. For 10 of 11 (91%) patients, combined stenting succeeded. 
Biliary obstruction occurring after enteral stent placement is more challenging to 
treat. Cannulation of papilla is more difficult or even impossible due to tumour 
tissue and stent in situ. For 40% (6/15) of the patients who developed jaundice after 
enteral SEMS, treatment of biliary obstruction by means of ERC was successful. In 
failure cases, though, PTC is a good treatment modality. 
In our comparative study on GOO in gastric cancer, the complication rates were 
equal between three palliation groups. In our other study on stenting incurable 
GOO, one fifth of the patients needed repeated stenting. Most of the complications 
were minor, and were managed endoscopically or conservatively. Only 2.9% of 
the patients underwent an operation due to persistent obstruction. Perforation is 
a rare, but dangerous complication of SEMS placement and can cause mortality. 
In our study on incurable GOO, four major complications occurred. Three of them 
were perforations and one was abscess with sepsis, and of four patients, three 
died. It is noteworthy that no serious late complications, such as perforation or 
migration, occurred. For patients stented due to gastric cancer, the median time to 
complications was three months. When considering short survival –a median of 2 
months- for stented patients, the majority of the patients die before complications, 
typically re-obstruction, develop. Therefore SEMS provides good palliation for 
these patients. In addition, the majority of the patients with poorest WHO scores 
(WHO 3 and 4) underwent stenting; thus our patient and treatment selection can 
be considered optimal.
In addition to overall survival, symptom-free survival is also an important issue 
when considering treatment alternatives. In our comparative study on gastric cancer 
and GOO, symptom-free survival was shortest for stented patients and longest for 
patients who underwent palliative resection. Interestingly, for all three treatment 
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groups, symptom-free survival was nearly similar to overall survival indicating that 
all three treatment modalities provide good palliation for selected patients. 
As shown by previous reports (Schmidt et al. 2009; van Hooft et al. 2009), QoL 
either improves or remains the same after stent placement of malignant GOO. GOO 
is a preterminal situation which leads to a weakening of the general condition of the 
patient. In GOO, the baseline assumption is gradual decrease in QoL. Thus, QoL 
remaining at the same level after SEMS placement should be considered as a good 
outcome. In our studies, QoL aspect was not assessed. In our cohort of incurable 
GOO, almost 75% of the patients avoided surgery by means of one SEMS placement. 
Therefore, QoL benefit for those stented patients with poor general health and poor 
survival may be assumed, however.
6.2 SELf-ExpANDING METAL STENTS IN BENIGN 
COLORECTAL OBSTRUCTION (III)
The standard treatment for benign strictures such as anastomotic strictures, 
diverticular strictures, Crohn`s disease strictures, and radiation strictures is dilation 
or surgery. Current data on stent placement for benign CRO is scarce with no 
randomized studies. Therefore, it cannot be considered as a standard of care for 
patients with CRO due to benign etiology. 
In our series, each of 21 patients had a specific indication for SEMS placement. 
Of ten DS patients, five underwent stent placement as a bridge to surgery and 
five patients were considered unsuitable for surgery due to high age, severe 
comorbidities, or obesity. Among ten DS patients, we treated eight AS patients, 
two Crohn`s disease patients, and one radiation stricture patient with SEMS. Our 
series shows similar results as two previously published reports (Dai et al. 2010; 
Vanbiervliet et al. 2013): SEMS seems to be beneficial for patients with AS. Of 
eight AS patients, stricture was resolved with SEMS in five (63%). All three patients 
with unfavourable outcome underwent operation eventually. For one patient with 
unsuccessful outcome, stricture was resolved at first, in spite of stent migration. The 
patient underwent laparoscopic anastomosis resection four months after stenting 
due to recurrent stricture, but even after the operation the stricture recurred. 
The remaining two patients with unfavourable outcome had a perforation and a 
permanent stoma was performed for both of them. These patients were complicated 
cases with a history of multiple operations, anastomotic leakages, and abscesses in 
the pelvis. Both patients had a strong objection to receiving a stoma. To date, the 
largest study of SEMS placement for AS found no predictive factors for recurrence 
or clinical efficacy (Vanbiervliet et al. 2013). Considering the medical history of 
the two patients with perforation in our study, SEMS placement was worth a try 
because surgical reanastomosis would have been technically challenging with no 
guarantee for avoidance of stoma, anyway.
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The advantage of a covered stent in temporary stent placement situations, such 
as AS, is that it is removable. A higher rate of migration is associated with covered 
stent. Interestingly, the migration seems not to be associated with initial clinical 
success or later recurrence of stricture (Vanbiervliet et al. 2013). As shown by a 
report, stent duration in its place for five days is enough for a stricture to resolve 
(Geiger et al. 2008). Therefore, migration of covered stent in the treatment of AS 
may be considered as a successful resolution of the stricture rather than an adverse 
effect. We used covered stents for 9 of 10 patients in AS. A migration occurred for 
three patients, and of three migrations only one was clinically relevant resulting in 
a new stent placement. For two patients, the SEMS migrated spontaneously after 
6 and 14 days. The strictures were resolved; for one patient permanently and for 
one patient for four months. 
In concordance with previous reports (Forshaw et al. 2006; Pommergaard et al. 
2009), high clinical failure and complication rate limit the usefulness of stenting in 
DS. In our study, only 30% truly gained benefit from stenting. The rest of the patients 
were operated on due to failure to decompress or due to a complication. For bridge 
to surgery patients, the outcome of SEMS placement was rather disappointing; all 
underwent emergency surgery, and Hartmann`s operation with end colostomy was 
performed for three of them. Stenting DS is associated with a high rate of delayed 
complications, and as suggested by Small et al. (Small et al. 2008), if an elective 
operation is planned it should be performed promptly, within a week of stenting. In 
our series, two late complications (perforation and colovesical fistula) might have 
been avoided if the patients had been operated in time. 
We treated only two CD patients with a stent; thus, it is impossible to evaluate 
the usefulness of stenting in general in Crohn`s strictures. Of importance are the 
strictures etiology and possibility of both early and late complications. As indicated 
by previous studies (Forshaw et al. 2006; Pommergaard et al. 2009; Small et al. 
2008), inflammatory disease of the bowel seems to be associated with a higher 
complication rate than AS. Our results on the impact of etiology on complications 
are similar; 67% of the complications occurred in DS and CD strictures. We used 
uncovered stents when stenting was considered as a definitive treatment. Uncovered 
stents are more prone to ulcerating the bowel and with an underlying transmural 
inflammation of the bowel complications such as perforation, fistula, or abscess may 
result. Noteworthy, for one patient with chronic and incurable CD, a perforation 
occurred four years after stenting. CD is also associated with higher risk of CRC 
than the general population (Ekbom et al. 1990), and the detection of dysplasia in 
colonoscopy is difficult. Therefore, in Crohn`s disease, stenting should be attempted 
only in special cases. 
Patients who undergo SEMS placement for benign causes should be carefully 
monitored for bowel decompression and for a possibility of complications. In the 
event of failure to decompress, an immediate endoscopy with dilation, re-stenting, 
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or insertion of decompression tube should be undertaken, and if these measures 
fail, surgery has to be performed.
6.3 SELf-ExpANDING METAL STENTS IN MALIGNANT 
COLORECTAL OBSTRUCTION (IV)
The purpose of the preoperative stent placement in acute obstruction is to enable an 
elective operation with primary anastomosis. In our study, a primary anastomosis 
was achieved in 90% of the elective operations. An end colostomy was performed 
for only one patient. Additionally, for three patients with middle and low rectal 
cancers, a defunctioning loop stoma was performed. The treatment of choice for 
rectal tumours located in the middle or low part of the rectum is total mesorectal 
excision (TME) with low anastomosis. For low anastomosis, a defunctioning 
loop stoma is recommended because it has been shown to reduce symptomatic 
anastomotic leakages and complications demanding reoperations (Matthiessen 
et al. 2007). As a stent may induce inflammation and fibrosis into surrounding 
tissues combined with radiotherapy often administered before rectal surgery, the 
subsequent operation may be technically more challenging than without the stent. 
Thus, for obstructive tumours located in the middle or low part of the rectum, 
preoperative loop stoma may provide a better option rather than a stent.
The results from randomized studies concerning preoperative SEMS placement 
and emergency surgery are inconsistent. In single center studies, the outcome for the 
preoperative SEMS group is better than for the emergency surgery group (Alcantara 
et al. 2011; Cheung et al. 2009). In multicentre studies, the high rate of complications 
related to SEMS led to premature closure of the studies (Pirlet et al. 2011; van 
Hooft et al. 2011). Technical success rates for SEMS placement were rather low, 
47% and 70%. The number of patients with complete obstruction was high in both 
studies which may have contributed to low technical success rates. Also, the centre’s 
experience in SEMS placement may have affected the outcome. In a French study 
(Pirlet et al. 2011), there were nine centres for 30 SEMS placements and in Dutch 
study (van Hooft et al. 2011), 25 centres for 47 SEMS placements. It is worth noting 
that patients who were successfully stented underwent an uneventful surgery and 
recovery in both multicentre studies. Thus, proper patient selection may decrease 
the amount of complications, as well as the centre`s high volume and expertise 
in colorectal SEMS placement. Stenting procedures for acute CRO should also be 
performed promptly, within eight hours, to avoid cecum necrosis and subsequent 
subtotal colectomy. Therefore, procedures should be performed in large enough 
centres with emergency surgery facilities. 
The high rate of silent and overt perforations associated with SEMS placement, 
and the possible negative impact on survival is alarming (Pirlet et al. 2011; van Hooft 
et al. 2011). The oncological outcome after SEMS placement is unclear, though. 
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According to reports, the long-term survival between SEMS and emergency surgery 
groups has been similar (Dastur et al. 2008; Saida et al. 2003). One study reported 
a worse outcome for the SEMS group than for the surgical group (Kim et al. 2009b). 
In a prospective non-randomized study, survival was significantly better for the 
preoperative SEMS group (p=0.004) (Gianotti et al. 2013). In our study, we had 
one perforation in the bridge to surgery group. Fortunately, the perforation was 
noticed during the SEMS placement which led to an emergency operation and the 
patient could avoid a stoma. Among 11 preoperatively stented patients, four patients 
had Dukes D carcinoma. With these four Dukes D patients included, the median 
survival for preoperatively stented patients was 3.5 years. With an absence of control 
group -based on our results- conclusions on the impact of stenting on survival 
cannot be drawn, however. When stenting potentially curable CRC patients, the 
rate of SEMS related perforations should be comparable with tumour perforations 
in surgery. Therefore, a high rate of overt and silent perforations associated with 
SEMS markedly limits the value of preoperative stenting in acute CRO. 
The efficacy of stenting for CRO caused by ECM is controversial. The clinical 
success rates, in particular, have shown significant variation in previous studies 
(Kim et al. 2013b; Trompetas et al. 2010). In our study we found that although the 
technical success rates were similar among CRC and ECM palliative stenting groups, 
for ECM the clinical success was achieved less frequently. Some have suggested 
that the etiology of the malignancy would contribute to the outcome (Keswani et al. 
2009); the best outcome is reported by Koreans where the predominant malignancy 
is gastric cancer (Kim et al. 2013b; Shin et al. 2008). At the same time, the worst 
outcome is found in studies where the most common etiology for CRO is gynecologic 
malignancy (Keswani et al. 2009; Trompetas et al. 2010). In our series, gynecologic 
malignancy was the most common etiology for CRO, and of the malignancies, only 
25% were derived from the upper-GI tract. 
Apparently, reasons for a clinical failure are multifactorial. When considering 
pelvic malignancies, such as gynecologic or prostate cancer, patients often receive 
radiotherapy. For ovarian cancer, in particular, carcinomatosis is common with 
multiple stricture sites (Dvoretsky et al. 1988). The contribution of all of these 
factors can make the bowel fixed and immobilized, with long and angled strictures. 
In our series, for ECM, the procedures lasted longer and also strictures were longer 
than for CRC, indicating that the circumstances for stenting might have been more 
challenging for ECM than for CRC. Consequently, even if stenting is technically 
possible the result may be a clinical failure. 
In study IV, of preoperative characteristics, median age, BMI, and ASA grade 
were similar between the groups. In the CRC group, CCI was higher indicating 
a higher prevalence of comorbidities. Despite the higher CCI and comorbidities, 
the median survival was significantly longer for CRC than for ECM patients. It 
seems that for ECM patients, and in particular for gynecological etiology, CRO is 
a preterminal event with limited survival. However, for patients achieving clinical 
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success after stenting, the complication, operation, and stoma rates were comparable 
between two palliative stenting groups. Thus, considering the limited survival and 
the burden of surgical treatment, SEMS placement as palliation is worth trying for 
ECM patients suffering symptoms of CRO.
Our high overall technical and clinical success rates are comparable with other 
reports (Khot et al. 2002; Sebastian et al. 2004). Of the stenting procedures, 97% 
were carried out by two highly experienced pancreatobiliary endoscopists. According 
to a report, strictures located in the proximal colon were associated with poorer 
outcome (Jung et al. 2010). In our cohort, 92% of the patients had a stricture distal 
to splenic flexure which may have affected on the technical and clinical success rates. 
A half of the strictures were incomplete which also may have contributed to the good 
outcome. Our total complication rate of 20% is also in comparison with previous 
studies (Khot et al. 2002; Sebastian et al. 2004). Of complications, only three 
perforations occurred early, within a week. When considering palliative stenting, 
the possibility of late complications should be considered when the treatment is 
planned. In our cohort, the median time to complication for CRC patients was 
almost four months. Interestingly, we had one perforation leading to death almost 
two months of SEMS placement. Of 11 late complications in the CRC group, only 
five required surgery; the remaining six could be managed either endoscopically 
or conservatively, however.
6.4 STRENGTHS AND LIMITATIONS Of THE STUDy
All the stenting procedures were performed in the Endoscopy Unit of Meilahti 
Hospital, which is a high volume unit specialized in demanding interventional 
endoscopy. Therefore, the endoscopists are experienced in pancreatobiliary 
procedures which diminish the risk for complications when considering duodenal 
and colorectal stent placements. The majority of the SEMS placements were 
performed by two endoscopists enabling standardized technique for stenting 
procedures. Moreover, the endoscopists who performed SEMS placements are GI-
surgeons which can be considered beneficial when evaluating treatment options 
and indications of stenting for surgical patients.
All the procedures are recorded into the endoscopy unit`s own database which 
enables the identification of the patients for analysis. The patient samples in studies 
I, II, and IV are large enough for drawing conclusions on stenting malignant GOO 
and CRO. Even in study III, the number of patients is large when compared to 
existing literature on benign stenting. 
The main limitation of this study is its retrospective aspect. As such, the 
information, of for example oral intake, may have been unreliable for some 
patients. Some follow-up data may have also been incomplete, and indications and 
treatment policies may have changed during the study period. In addition to being 
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retrospective, the studies were performed in a single-centre and the results may 
not be adjusted to general practice in every surgical unit. Furthermore, the studies 
were non-randomized which may cause selection bias between treatment groups 
in comparative studies (II, IV). In particular in study II, the fittest and youngest 
patients may have been selected to the PR group, and older patients are more likely 
offered to undergo SEMS placement. Possibly the patients who underwent palliative 
resection had less advanced disease, and in particular if they received chemotherapy, 
they survived longer. In gastric cancer and GOO, some variables may have emerged 
statistically significant if the number of patients who were operated on would have 
been larger giving sufficient statistical power. Finally, when considering palliative 
treatment for incurable malignancies of the GI-tract, the lack of QoL aspect is also 
a major limitation in this study.
6.5 fUTURE ASpECTS
Many aspects of stenting GOO and CRO are still developing or require further 
studies.
The stents and stenting techniques are developing continuously. In GOO, 
individually designed stents that adjust to the anatomy of the proximal gastric 
lumen may prevent migration and stent obstruction. In benign colorectal strictures, 
biodegradable stents may be a safer option than SEMS. 
The survival benefit of non-curative resection in the absence of major symptoms 
in gastric cancer is unclear. A randomized study comparing chemotherapy alone 
and combined chemotherapy and resection is warranted. Thereby, the results from 
the randomized study would help in choosing an optimal treatment also for patients 
with advanced gastric cancer and symptoms of GOO.  In stenting malignant CRO 
as a bridge to surgery, the impact of overt and silent perforations on long-term 
oncological outcome is still unclear. Further studies are needed to define the value 
of preoperative stenting in acute malignant CRO. In benign CRO, SEMS seems to be 
a potential treatment alternative for selected patients with AS. The utility of SEMS 
in AS should be proved in a randomized study comparing EBD and SEMS, however.
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7. CONCLUSIONS
1) In the study of 104 patients with incurable GOO and limited survival we found 
that stent placement provides good palliation. Stenting restores oral intake rapidly 
with an acceptable rate of complications and a short hospital stay. Combined stenting 
of concomitant biliary and enteral stenting carries a high success rate of 90%. 
2) In patients with advanced gastric cancer and GOO, clinical condition of the 
patient affects survival and should be carefully evaluated when deciding treatment. 
For patients unfit for surgery, stenting provides rapid improvement in oral intake 
with short hospital stay. Stenting should be the treatment of choice for poor 
performance status patients. PR as a treatment modality seems to provide survival 
benefit. Therefore, PR should be considered as a treatment modality for patients 
fit for surgery.  In addition, chemotherapy seems to provide survival benefit for 
patients with advanced gastric cancer and GOO.
3) Our study on stenting benign CRO adds information to scarce existing data 
on the subject. SEMS seems to be a good treatment option in resistant anastomotic 
strictures for selected patients unfit for surgery. In diverticular disease, stenting 
seems less beneficial with lower clinical success rate and higher rate of complications. 
If stenting is attempted in diverticular disease, patients need careful monitoring after 
procedure. After stenting DS, a definitive operation should be performed promptly, 
at the latest within a month. 
4) Stenting malignant CRO should be performed in high volume centres due to 
the possibility of major complications, such as perforations. SEMS as a bridge to 
surgery is associated with a high rate of primary anastomosis. A possibility of overt 
or silent perforations limits the value of preoperative stenting in malignant CRO, 
however. Palliative stenting in incurable malignancies provides good palliation. 
Higher clinical failure rate is associated with CRO caused by ECM. 
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